Amyris (AMRSQ) 10-Q 14 Aug 17 2017 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2017	Aug. 11, 2017
Document Information [Line Items]
Entity Registrant Name	AMYRIS, INC.
Entity Central Index Key	1,365,916
Trading Symbol	amrs
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		37,606,558
Document Type	10-Q
Document Period End Date	Jun. 30, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q2
Amendment Flag	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Assets
Cash and cash equivalents	$ 5,078	$ 27,150
Restricted cash	3,815	4,326
Short-term investments	1,556	1,374
Accounts receivable, net of allowance of $501 and $478, respectively	15,958	13,105
Related party accounts receivable, net of allowance of $23 and $23, respectively	1,431	872
Inventories	5,729	6,213
Prepaid expenses and other current assets	7,440	6,083
Total current assets	41,007	59,123
Property, plant and equipment, net	49,303	53,735
Restricted cash, non-current	958	957
Equity and loans in affiliates	94	34
Other assets	20,783	15,464
Goodwill and intangible assets	560	560
Total assets	112,705	129,873
Liabilities, Mezzanine Equity and Stockholders' Deficit
Accounts payable	14,657	15,315
Deferred revenue	5,001	5,288
Accrued and other current liabilities	29,275	29,188
Capital lease obligation, current portion	598	922
Debt, current portion	7,954	25,853
Related party debt, current portion	5,331	33,302
Total current liabilities	62,816	109,868
Capital lease obligation, net of current portion	33	334
Long-term debt, net of current portion	111,112	128,744
Related party debt, net of current portion	40,920	39,144
Deferred rent, net of current portion	8,445	8,906
Deferred revenue, net of current portion	6,650	6,650
Derivative liabilities	58,606	6,894
Other liabilities	5,639	7,841
Total liabilities	294,221	308,381
Commitments and contingencies (Note 6)
Stockholders’ deficit:
Preferred Stock - $0.0001 par value, 5,000,000 and 5,000,000 shares authorized as of June 30, 2017 and December 31, 2016, respectively, and 3,330 and 0 shares issued and outstanding as of June 30, 2017 and December 31, 2016, respectively
Common stock - $0.0001 par value, 250,000,000 and 500,000,000 shares authorized as of June 30, 2017 and December 31, 2016, respectively; 25,272,420 and 18,273,921 shares issued and outstanding as of June 30, 2017 and December 31, 2016, respectively	3	2
Additional paid-in capital - common stock and other	1,012,906	990,895
Accumulated other comprehensive loss	(42,003)	(40,904)
Accumulated deficit	(1,171,189)	(1,134,438)
Total Amyris, Inc. stockholders’ deficit	(200,283)	(184,445)
Noncontrolling interest	937	937
Total stockholders' deficit	(199,346)	(183,508)
Total liabilities, mezzanine equity and stockholders' deficit	112,705	129,873
Contingently Redeemable Common Stock [Member]
Liabilities, Mezzanine Equity and Stockholders' Deficit
Mezzanine Equity	5,000	5,000
Convertible Preferred Stock [Member]
Liabilities, Mezzanine Equity and Stockholders' Deficit
Mezzanine Equity	$ 12,830

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Allowance for doubtful accounts	$ 501	$ 478
Related party accounts receivable allowace	$ 23	$ 23
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	3,330	0
Preferred stock, shares outstanding (in shares)	3,330	0
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	250,000,000	500,000,000
Common stock, shares issued (in shares)	25,272,420	18,273,921
Common stock, shares outstanding (in shares)	25,272,420	18,273,921

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Renewable product sales	$ 12,729,000	$ 4,922,000	$ 21,021,000	$ 8,062,000
Grants and collaborations revenue	12,950,000	4,677,000	17,639,000	10,347,000
Total revenues	25,679,000	9,599,000	38,660,000	18,409,000
Cost and operating expenses
Cost of products sold	17,279,000	7,891,000	30,047,000	19,068,000
Research and development	14,249,000	13,176,000	28,956,000	25,082,000
Sales, general and administrative	15,949,000	11,408,000	28,799,000	23,674,000
Total cost and operating expenses	47,477,000	32,475,000	87,802,000	67,824,000
Loss from operations	(21,798,000)	(22,876,000)	(49,142,000)	(49,415,000)
Other income (expense):
Interest income	43,000	82,000	105,000	139,000
Interest expense	(9,303,000)	(9,704,000)	(21,486,000)	(18,062,000)
Gain from change in fair value of derivative instruments	35,775,000	20,934,000	38,114,000	42,612,000
Loss upon extinguishment of debt	(3,624,000)	(433,000)	(3,528,000)	(649,000)
Other expense, net	(163,000)	(1,431,000)	(545,000)	(3,246,000)
Total other income	22,728,000	9,448,000	12,660,000	20,794,000
Income (loss) before income taxes	930,000	(13,428,000)	(36,482,000)	(28,621,000)
Provision for income taxes	(310,000)	(138,000)	(269,000)	(253,000)
Net income (loss) attributable to Amyris, Inc.	620,000	(13,566,000)	(36,751,000)	(28,874,000)
Less deemed dividend (capital distribution to related parties)	(8,648,000)		(8,648,000)
Less deemed dividend related to beneficial conversion feature on Series A preferred stock	(562,000)		(562,000)
Less cumulative dividends on Series A and Series B preferred stock	(1,675,000)		(1,675,000)
Net loss attributable to Amyris, Inc. common stockholders	$ (10,265,000)	$ (13,566,000)	$ (47,636,000)	$ (28,874,000)
Net loss per share attributable to common stockholders:
Basic (in dollars per share)	$ (0.44)	$ (0.91)	$ (2.24)	$ (2)
Diluted (in dollars per share)	$ (0.44)	$ (1.67)	$ (2.24)	$ (3.46)
Weighted-average shares of common stock outstanding used in computing net loss per share of common stock:
Basic (in shares)	23,155,874	14,874,135	21,226,013	14,426,247
Diluted (in shares)	23,155,874	17,526,410	21,226,013	17,253,961

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Comprehensive loss:
Net loss attributable to Amyris, Inc. common stockholders	$ (10,265)	$ (13,566)	$ (47,636)	$ (28,874)
Foreign currency translation adjustment, net of tax	(1,422)	4,593	(1,099)	9,281
Comprehensive loss attributable to Amyris, Inc. common stockholders	$ (11,687)	$ (8,973)	$ (48,735)	$ (19,593)

Condensed Consolidated Stateme6

Condensed Consolidated Statements of Stockholders' Deficit and Mezzanine Equity (Unaudited) - USD ($) $ in Thousands	Series A Preferred Stock [Member]Preferred Stock [Member]	Series A Preferred Stock [Member]Common Stock [Member]	Series A Preferred Stock [Member]Preferred Stock Including Additional Paid in Capital [Member]	Series A Preferred Stock [Member]AOCI Attributable to Parent [Member]	Series A Preferred Stock [Member]Retained Earnings [Member]	Series A Preferred Stock [Member]Noncontrolling Interest [Member]	Series A Preferred Stock [Member]Mezzanine Equity, Common Stock [Member]	Series A Preferred Stock [Member]Mezzanine Equity, Preferred Stock [Member]	Series A Preferred Stock [Member]	Series B Preferred Stock [Member]Preferred Stock [Member]	Series B Preferred Stock [Member]Common Stock [Member]	Series B Preferred Stock [Member]Preferred Stock Including Additional Paid in Capital [Member]	Series B Preferred Stock [Member]AOCI Attributable to Parent [Member]	Series B Preferred Stock [Member]Retained Earnings [Member]	Series B Preferred Stock [Member]Noncontrolling Interest [Member]	Series B Preferred Stock [Member]Mezzanine Equity, Common Stock [Member]	Series B Preferred Stock [Member]Mezzanine Equity, Preferred Stock [Member]	Series B Preferred Stock [Member]	Preferred Stock [Member]	Common Stock [Member]	Preferred Stock Including Additional Paid in Capital [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Noncontrolling Interest [Member]	Mezzanine Equity, Common Stock [Member]	Mezzanine Equity, Preferred Stock [Member]	Total
Balance at Jun. 30, 2016																				$ 22	$ 949,803	$ (37,917)	$ (1,065,978)	$ (114)	$ 5,000		$ (154,184)
Balance (in shares) at Dec. 31, 2015																				13,742,019
Balance at Dec. 31, 2015																				$ 21	926,216	(47,198)	(1,037,104)	(391)			(158,456)
Issuance of common stock upon conversion of debt (in shares)																				547,992
Issuance of common stock upon conversion of debt																				$ 1	8,637						8,638
Issuance of common stock for settlement of debt principal payments (in shares)																				566,049
Issuance of common stock for settlement of debt principal payments																					3,289						3,289
Shares issued upon ESPP purchase																					123						123
Issuance of contingently redeemable common stock (in shares)																				292,398
Issuance of contingently redeemable common stock																									5,000
Issuance of warrants with debt private placement																					3,971						3,971
Acquisition of noncontrolling interest																					(323)			277			(46)
Contribution upon restructuring of Fuels JV																					4,251						4,251
Issuance of common stock upon exercise of stock options, net of restricted stock (in shares)																				9
Issuance of common stock upon exercise of stock options, net of restricted stock
Shares issued from restricted stock settlement (in shares)																				64,305
Shares issued from restricted stock settlement																					(201)						(201)
Shares issued upon ESPP purchase (in shares)																				15,122
Stock-based compensation																					3,840						3,840
Foreign currency translation adjustment, net of tax																						9,281					9,281
Net loss																							(28,874)				(28,874)
Balance (in shares) at Jun. 30, 2016																				15,227,894
Issuance of Series B preferred stock upon conversion of debt, net of issuance costs of $634 (in shares)																			40,204
Issuance of Series B preferred stock upon conversion of debt, net of issuance costs of $634																										11,530
Balance at Jun. 30, 2017																				$ 3	1,012,906	(42,003)	(1,171,189)	937	5,000	12,830	(199,346)
Balance (in shares) at Dec. 31, 2016																				18,273,921
Balance at Dec. 31, 2016																				$ 2	990,895	(40,904)	(1,134,438)	937	5,000		(183,508)
Issuance of preferred stock for cash (in shares)	22,140									30,700
Issuance of preferred stock for cash																	$ 1,300
Issuance of shares due to rounding from reverse stock split (in shares)																				6,473
Issuance of shares due to rounding from reverse stock split
Issuance of common stock upon conversion of preferred stock (in shares)																			(18,840)	2,990,374
Issuance of common stock upon conversion of preferred stock
Issuance of common stock upon conversion of debt (in shares)																				2,257,786
Issuance of common stock upon conversion of debt																					14,154						14,154
Issuance of common stock for settlement of debt principal payments (in shares)																				1,246,165
Issuance of common stock for settlement of debt principal payments																				$ 1	10,707						10,708
Issuance of common stock for settlement of debt interest payments																					3,436						3,436
Issuance of common stock for settlement of debt interest payments (in shares)																				400,967
Shares issued upon ESPP purchase																					69						69
Deemed dividend upon conversion of debt into Series A and Series B preferred stock																					(8,648)						$ (8,648)
Issuance of common stock upon exercise of stock options, net of restricted stock (in shares)																				134							133
Issuance of common stock upon exercise of stock options, net of restricted stock
Shares issued from restricted stock settlement (in shares)																				79,841
Shares issued from restricted stock settlement																					(391)						(391)
Shares issued upon ESPP purchase (in shares)																				16,759
Stock-based compensation																					2,684						2,684
Foreign currency translation adjustment, net of tax																						(1,099)					(1,099)
Net loss																							$ (36,751)				$ (36,751)
Balance (in shares) at Jun. 30, 2017																			74,204	25,272,420

Condensed Consolidated Stateme7

Condensed Consolidated Statements of Stockholders' Deficit and Mezzanine Equity (Unaudited) (Parentheticals) $ in Thousands	6 Months Ended
	Jun. 30, 2017USD ($)
Series A Preferred Stock [Member]
Issuance costs	$ 562
Series B Preferred Stock [Member]
Issuance costs	$ 634

Condensed Consolidated Stateme8

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Operating activities
Net loss	$ (36,751,000)	$ (28,874,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	5,550,000	5,720,000
Loss on disposal of property, plant and equipment	(161,000)	(122,000)
Stock-based compensation	2,684,000	3,840,000
Amortization of debt discount and issuance costs	7,637,000	7,415,000
Receipt of equity in connection with collaboration arrangements revenue	(2,660,000)
Loss upon extinguishment of debt	3,528,000	649,000
Gain from change in fair value of derivative instruments	(38,115,000)	(42,612,000)
Loss on foreign currency exchange rates	63,000	1,083,000
Changes in assets and liabilities:
Accounts receivable	(3,723,000)	(183,000)
Related party accounts receivable	214,000	587,000
Inventory	409,000	1,910,000
Prepaid expenses and other assets	(4,220,000)	1,695,000
Accounts payable	(1,739,000)	1,190,000
Accrued and other liabilities	8,392,000	8,132,000
Deferred revenue	(838,000)	939,000
Deferred rent	(449,000)	(344,000)
Net cash used in operating activities	(60,179,000)	(38,975,000)
Investing activities
Purchase of short-term investments	(3,966,000)	(2,366,000)
Maturities of short-term investments	3,895,000	2,585,000
Change in restricted cash	(982,000)	7,000
Purchases of property, plant and equipment, net of disposals	(264,000)	(400,000)
Net cash used in investing activities	(1,317,000)	(174,000)
Financing activities
Proceeds from sale of convertible preferred stock	50,661,000
Proceeds from exercises of common stock options, net of repurchase	69,000	123,000
Employees' taxes paid upon vesting of restricted stock units	(110,000)	(201,000)
Proceeds from issuance of contingently redeemable equity		5,000,000
Principal payments on capital leases	(764,000)	(506,000)
Change in restricted cash related to contingently redeemable equity	1,478,000	(5,000,000)
Proceeds from debt issued	12,455,000	9,950,000
Proceeds from debt issued to related party		25,000,000
Principal payments on debt	(24,372,000)	(6,573,000)
Net cash provided by financing activities	39,417,000	27,793,000
Effect of exchange rate changes on cash and cash equivalents	7,000	186,000
Net decrease in cash and cash equivalents	(22,072,000)	(11,170,000)
Cash and cash equivalents at beginning of period	27,150,000	11,992,000
Cash and cash equivalents at end of period	5,078,000	822,000
Cash paid for interest	4,526,000	3,735,000
Supplemental disclosures of non-cash investing and financing activities:
Acquisition of property, plant and equipment under accounts payable, accrued liabilities and notes payable	(1,189,000)	(521,000)
Financing of equipment	138,000	1,276,000
Financing of insurance premium under notes payable	(191,000)	(315,000)
Issuance of common stock for settlement of debt principal and interest payments	3,233,000	3,289,000
Issuance of convertible preferred stock upon conversion of debt	40,204,000
Issuance of common stock upon conversion of debt	28,702,000	8,638,000
Interest capitalized to debt	1,745,000	2,052,000
Non-cash investment in joint venture		600,000
Cancellation of debt and accrued interest on disposal of interest in affiliate		$ 4,252,000

Note 1 - The Company

Note 1 - The Company	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Nature of Operations [Text Block]	1. Amyris, Inc. (or the Company) is a leading industrial biotechnology company that is applying its technology platform to engineer, manufacture and sell high performance products into the Health and Nutrition, Personal Care and Performance Materials markets. The Company's proven technology platform enables the Company to rapidly engineer microbes and use them as catalysts to metabolize renewable, plant-sourced sugars into large volume, high-value ingredients. The Company's biotechnology platform and industrial fermentation process replace existing complex and expensive chemical manufacturing processes. The Company has successfully used its technology to develop and produce at commercial volumes five July 17, 2003 April 15, 2010. The Company believes that industrial synthetic biology represents a third three Liquidity The Company expects to fund its operations for the foreseeable future with cash and investments currently on hand, with cash inflows from collaborations and grants, with cash contributions from product sales, and if needed, with new equity and debt financings. For the remainder of 2017 2018, The Company has incurred significant operating losses since its inception and expects to continue to incur losses and negative cash flows from operations into 2018. June 30, 2017, $21.8 $1.2 $6.6 one not Our ability to continue as a going concern will depend, in large part, on our ability to achieve positive cash flows from operations during the next 12 2017 2018 If the Company is unable to continue as a going concern, it may may As of June 30, 2017, $26.0 $165.3 $13.3 twelve $11.2 Subsequent to June 30, 2017, $50 14,

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Significant Accounting Policies [Text Block]	2. Basis of Presentation and Principles of Consolidation The consolidated financial statements include the results of wholly-owned and partially-owned subsidiaries in which the Company has a controlling interest with all significant intercompany accounts and transactions eliminated in consolidation. Unaudited Interim Financial Information The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (or U.S. GAAP) for interim financial information and Article 10 X not June 30, 2017, three six June 30, 2017 2016, six June 30, 2017 2016. December 31, 2016 not 10 10 December 31, 2016. Reverse Stock Split On June 5, 2017, 1 15 $0.0001 500,000,000 250,000,000. not first first may The par value, number of shares outstanding and number of authorized shares of preferred stock were not Use of Estimates The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the periods reported. Actual results could differ from these estimates, and such differences may The accompanying interim condensed consolidated financial statements and related disclosures are unaudited, have been prepared on the same basis as the annual consolidated financial statements, except for the impact of adoption of certain accounting standards as described below, and in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for a fair statement of the results of operations for the periods presented. In the six June 30, 2017 • ASU 2015 11, Inventory (Topic 330 • ASU 2016 06, Derivatives and Hedging (Topic 815 • ASU 2016 09, Compensation—Stock Compensation (Topic 718 None Recent Accounting Pronouncements Revenue Recognition May 2014, 2014 09, 606 , Revenue from Contracts with Customers 605, Revenue Recognition 2015 2016, first 2018. may first 2018. may not Financial Instruments January 2016, 2016 01, Financial Instruments-Overall (Subtopic 825 10 first 2018. 2016 01 not Leases February 2016, 2016 02, Leases (Topic 842 first 2019 Credit Losses of Financial Instruments June 2016, 2016 13, Financial Instruments-Credit Losses (Topic 326 2016 13 first 2020 Classification of Cash Flow Elements August 2016, 2016 15, Statement of Cash Flows (Topic 230 first 2018 Restricted Cash in Statement of Cash Flows November 2016, 2016 18, Statement of Cash Flows (Topic 230 first 2018 2016 18 Derecognition of Nonfinancial Assets February 2017, 2017 05, Other Income—Gains and Losses from the Derecognition of Nonfinancial Assets (Subtopic 610 20 606 not 1 not 2 not first 2018 When Changes to Share-based Payment Awards Must Be Accounted for as Modifications May 2017, 2017 09, Compensation—Stock Compensation (Topic 718 not first 2018

Note 3 - Fair Value of Financia

Note 3 - Fair Value of Financial Instruments	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Financial Instruments Disclosure [Text Block]	3. The inputs to the valuation techniques used to measure fair value are classified into the following categories: Level 1: Level 2: Level 3: not There were no June 30, 2017, Level 1 Level 2 Level 3 Balance as of Financial Assets Money market funds $ 5,078 $ — $ — $ 5,078 Certificates of deposit 5,371 — — 5,371 Total financial assets $ 10,449 $ — $ — $ 10,449 Financial Liabilities Compound embedded derivative liability $ — $ — $ 56,222 $ 56,222 Currency interest rate swap derivative liability — — 2,384 2,384 Total financial liabilities $ — $ — $ 58,606 $ 58,606 As of December 31, 2016, Level 1 Level 2 Level 3 Balance as of Financial Assets Money market funds $ 1,549 $ — $ — $ 1,549 Certificates of deposit 1,373 — — 1,373 Total financial assets $ 2,922 $ — $ — $ 2,922 Financial Liabilities Compound embedded derivative liability $ — $ — $ 4,135 $ 4,135 Currency interest rate swap derivative liability — — 3,343 3,343 Total financial liabilities $ — $ — $ 7,478 $ 7,478 The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability. The fair values of money market funds and certificates of deposit are based on fair values of identical assets. The fair values of the currency interest rate swaps are based on the present value of expected future cash flows and assumptions about current interest rates and the Company's creditworthiness. The method of determining the fair value of the compound embedded derivative liabilities is described subsequently in this note. Market risk associated with the fixed and variable rate long-term loans payable, credit facilities and convertible notes relates to the potential reduction in fair value and negative impact to future earnings, from an increase in interest rates. Market risk associated with the compound embedded derivative liabilities relates to the potential reduction in fair value and negative impact to future earnings from a decrease in interest rates. The carrying amounts of certain financial instruments, such as cash equivalents, accounts receivable, accounts payable and accrued liabilities, approximate fair value due to their relatively short maturities and low market interest rates, if applicable. Loans payable, credit facilities and convertible notes were recorded at carrying value, which was representative of fair value at the date of acquisition. The Company estimates the fair value of loans payable and credit facilities using market observable inputs (Level 2 3 June 30, 2017 $16.6 $49.8 $99.0 June 30, 2017 $13.4 $32.6 $95.8 The following table provides a reconciliation of the beginning and ending balances for the compound embedded derivative liabilities measured at fair value using significant unobservable inputs (Level 3 2017 Balance at January 1 $ 4,135 Gain from change in fair value of derivative liabilities (in statements of operations) (32,210 ) Additions 93,675 Derecognition on extinguishment or conversion (9,378 ) Balance at June 30 $ 56,222 The compound embedded derivative liabilities represent the fair value of the equity cash warrants, conversion options and "make-whole" provisions of the May 2017 May 2017 2014 144A 2015 144A 5, June 30, 2017 December 31, 2016, $56.2 $4.1 The market-based assumptions and estimates used in applying a Monte Carlo simulation approach and Black-Scholes-Merton option value approach for valuing the compound embedded derivative liabilities include amounts in the following ranges/amounts: June 30, 2017 May 11, 2017 December 31, 2016 Risk-free interest rate 1.29% - 1.93% 1.93% 0.55% - 1.31% Risk-adjusted yields 4.50% - 28.93% — 12.80% - 22.93% Stock-price volatility 45% - 80% 80% 45% Probability of change in control 5% 5% 5% Stock price $3.18 $4.95 $0.73 Credit spread 3.15% - 27.57% — 11.59% - 21.64% Estimated conversion dates 2017 - 2022 2017 - 2022 2017 - 2019 Changes in valuation assumptions can have a significant impact on the valuation of the embedded derivative liabilities. For example, all other things being equal, a decrease/increase in the Company’s stock price, probability of change of control, credit spread, term to maturity/conversion or stock price volatility decreases/increases the valuation of the liabilities, whereas a decrease/increase in risk adjusted yields or risk-free interest rates increases/decreases the valuation of the liabilities. Certain of the Convertible Notes also include conversion price adjustment features whereby, for example, issuances of equity or equity-linked securities by the Company at prices lower than the conversion price then in effect for such notes result in a reset or adjustment of the conversion price of such notes, which increases the value of the embedded derivative liabilities. See Note 5, On April 21, 2017, 850,115 $3.2 40%, 0.92%, zero 45%. In June 2012, 5, R$22.0 US$6.7 June 30, 2017 3.94%. Changes in the fair value of the compound embedded derivative liabilities are recognized in “Gain from change in fair value of derivative instruments" in the condensed consolidated statements of operations are as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, Type of Derivative Contract 2017 2016 2017 2016 Compound embedded derivative liabilities $ 35,814 $ 19,659 $ 36,315 $ 40,492 Currency interest rate swaps (39 ) 1,275 1,799 2,120 Total gain from change in fair value of derivative instruments $ 35,775 $ 20,934 $ 38,114 $ 42,612

Note 4 - Balance Sheet Componen

Note 4 - Balance Sheet Components	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Supplemental Balance Sheet Disclosures [Text Block]	4. Inventories Inventories are stated at the lower of cost or net realizable value and are comprised of the following (in thousands): June 30, December 31, Raw materials $ 2,937 $ 3,159 Work-in-process 1,379 1,848 Finished goods 1,413 1,206 Inventories $ 5,729 $ 6,213 Property, Plant and Equipment, net Property, plant and equipment, net is comprised of the following (in thousands): June 30, December 31, 2016 Machinery and equipment $ 84,785 $ 82,688 Leasehold improvements 38,770 38,785 Computers and software 9,619 9,585 Buildings 4,630 4,699 Furniture and office equipment 2,324 2,333 Vehicles 133 164 Land 460 460 Construction in progress 367 2,216 141,088 140,930 Less: accumulated depreciation and amortization (91,785 ) (87,195 ) Property, plant and equipment, net $ 49,303 $ 53,735 Property, plant and equipment, net includes $3.4 $3.1 June 30, 2017 December 31, 2016, $0.3 $0.6 June 30, 2017 December 31, 2016, Depreciation and amortization expense, including amortization of assets under capital leases was $2.7 $2.8 three June 30, 2017 2016, $5.4 $5.7 six June 30, 2017 2016, Other Assets (noncurrent) Other assets are comprised of the following (in thousands): June 30, December 31, Recoverable taxes from Brazilian government entities $ 15,443 $ 13,723 Cost-method investment 3,233 — Deposits on property and equipment, including taxes 909 291 Other 1,198 1,450 Total other assets $ 20,783 $ 15,464 Accrued and Other Current Liabilities Accrued and other current liabilities are comprised of the following (in thousands): June 30, December 31, Withholding tax related to conversion of related party notes $ 1,370 $ 1,370 Professional services 5,943 6,876 SMA relocation accrual 3,587 3,641 Accrued interest 4,133 4,847 Tax-related liabilities 2,741 2,610 Accrued vacation 2,274 2,034 Payroll and related expenses 3,512 4,310 Deferred rent, current portion 1,122 1,111 Contractual obligations to contract manufacturers 2,698 — Other 1,895 2,389 Total accrued and other current liabilities $ 29,275 $ 29,188

Note 5 - Debt and Mezzanine Equ

Note 5 - Debt and Mezzanine Equity	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Debt Disclosure [Text Block]	5. Debt and mezzanine equity are comprised of the following (in thousands): June 30, 2017 December 31, 2016 Senior secured loan facility $ 27,999 $ 27,658 BNDES credit facility 577 1,172 FINEP credit facility 534 696 Guanfu credit facility 20,645 19,564 Total credit facilities 49,755 49,090 Convertible notes 54,471 78,981 Loans payable 14,592 26,527 Related party convertible notes 44,499 42,754 Related party loan payable 2,000 29,691 Total debt 165,317 227,043 Less: current portion (13,285 ) (59,155 ) Long-term debt, net of current portion $ 152,032 $ 167,888 Mezzanine equity Contingently redeemable common stock $ 5,000 $ 5,000 Convertible preferred stock $ 12,830 $ — Senior Secured Loan Facility In March 2014, $25.0 June 2014, March 2015 November 2015 $30,960,000, $15,960,000 $1,450,000 In June 2016, 8, October 2016, fourth $1 January 11, 2017, October 15, 2018 No January 2017, fifth $3 As of June 30, 2017, $27.8 $0.6 may FINEP Credit Facility As of June 30, 2017 December 31, 2016, R$1.8 US$0.5 R$2.3 US$0.7 R$6.0 US$1.8 June 30, 2017 Guanfu Credit Facility On October 26, 2016, $25.0 three November 2016, December 31, 2016, $25.0 five 10% March 31, 2017. may, 100% Upon the occurrence of certain specified events of default under the Guanfu Credit Facility, the Company will grant to Guanfu an exclusive, royalty-free, global license to certain intellectual property useful in connection with Guanfu’s existing commercial relationship with the Company. In addition, in the event the Company fails to pay interest or principal under the Guanfu Note within ten 90% 90 two Convertible Notes Fidelity In February 2012, $25.0 3% March 1, 2017 $106.023 October 2015, $57.6 “2015 144A $8.8 $9.7 December 28, 2016, $19.1 2015 144A 1:1.25 i.e. $1.00 $1.25 2015 144A 1933, January 11, 2017. $19.1 2015 144A not 2015 144A $0.1 first 2015 144A fourth October 15, 2018. fourth 2014 144A In May 2014, $75.0 6.50% 2019 2014 144A $72.0 $24.7 2014 144A $9.7 October 2015, $57.6 “2015 144A $18.3 $22.9 2014 144A 2014 144A 6.50% May 15 November 15 2014 144A May 15, 2019, 2014 144A 17.8073 $1,000 2014 144A $56.16 5, 2014 144A 2015 144A In October 2015, $57.6 9.50% 2019 2015 144A 2015 144A $54.4 $18.3 $22.9 2014 144A $8.8 $9.7 2015 144A 2015 144A 9.50% April 15 October 15 2015 144A April 15, 2016 October 15, 2016 April 15, 2017 2015 144A April 15, 2019 The 2015 144A 48.3395 $1,000 2015 144A June 6, 2017, $20.69 2015 144A April 15, 2019), 0.75%. may 92.5% 10 June 30, 2017, January 2017, $19.1 2015 144A 2015 144A $15.3 2015 144A 2015 144A not 2015 144A not 2015 144A 2015 144A 19.99% December 28, 2016 ( 2015 144A 2015 144A May 2016 In May 2016, May 2016 $15.0 May 2016 Pursuant to the May 2016 May 2016 three May 2016, September, 2016 October 2016 $14.9 The May 2016 October 2016. December 2016 April 2017 On December 1, 2016, December 2016 $10.0 December 2016 $9.9 December 2016 May 2017. On April 13, 2017, April 2017 $15.0 April 2017 April 2017 first third April 2017 April 2017 On April 17, 2017, April 2017 $7.0 $7 $6.9 $7 May 2017. On May 2, 2017, April 2017 December 2016 April 2017 December 2016 April 2017 December 2016 April 2017 may 10% 20% 80% December 2016 April 2017 five 70% five On June 30, 2017, April 2017 $3.0 $3 $3.0 $3 $3 $3 10 14, The Amended Notes are general unsecured obligations of the Company. Unless earlier converted or redeemed, the Amended Notes will mature on or about the 18 The Amended Notes are payable in monthly installments, in either cash at 118% not 50% $200,000. The Amended Notes contain customary terms and covenants, including certain events of default after which the holders may 118% In the event of a Fundamental Transaction (as defined in the Amended Notes), holders of the Amended Notes may 118% The Company has the right to redeem the Amended Notes for cash, in whole, at any time, or in part, from time to time, at a redemption price equal to 118% The Amended Notes are convertible from time to time, at the election of the holders, into shares of common stock at an conversion price of $28.50 Notwithstanding the foregoing, the holders will not not 4.99% not 9.99%, not 61 3,792,779 April 2017 April 2017 218,817 For as long as they hold Amended Notes or shares of common stock issued under the Amended Notes, the holders may not $15.75 $15.00, may not As of June 30, 2017, $19.1 December 31, 2016, December 2016 $9.9 See Note 14, June 30, 2017. Related Party Convertible Notes Total R&D Convertible Notes In July 2012 December 2013, $105.0 1.5% March 2017 ( January 2015 In July 2015, $5.0 $70 2.0 5, In March 2016, one 75% 25% $1.3 $2.8 July 29, 2015) 50,000, $5.0 $3.7 25% $4.2 As of June 30, 2017 December 31, 2016, $3.7 $3.7 In February 2017, March 1, 2017 May 15, 2017. May 2017, second May 15, 2017 March 31, 2018, ( 1.5% 12.0%, May 16, 2017, December 31, 2017 $46.20 10 August 2013 In August 2013, August 2013 $73.0 August 2013 24 In October 2013, $35.0 February 2, 2014 5.5% October 16, 2013 first August 2013 In October 2013, August 2013 first August 2013 $7.6 first $9.2 first October 2013, first August 2013 $51.8 $7.6 $44.2 $35.0 $9.2 $35.0 $9.2 $19.9 sixty October 16, 2018) $2.44 15% 60 August 7, 2013, 5% six six June 30, 2017, may six In December 2013, August 2013 $3.0 second August 2013 January 2014, $34.0 second August 2013 $25.0 $3.0 $6.0 $6.0 $9.4 sixty January 15, 2019). 10%, twelve June 30, 2017, The conversion price of the Tranche I Notes and Tranche II Notes is approximately $7.425 June 30, 2017. As of June 30, 2017 December 31, 2016, $22.1 $21.8 $0.0 $0.0 5, Loans Payable In July 2012, July 2012 July 2012 R$52.0 US$15.7 June 30, 2017 R$68.0 US$20.6 June 30, 2017 July 2012 R$52.0 US$15.7 June 30, 2017 July 15, 2022 5.5% 30 first two August 15, 2014, June 30, 2017 December 31, 2016, $10.0 $11.1 Exchange (Debt Conversion - Related Party Transaction) In July 2015, $71.0 July 29, 2015) $70.0 $34.50 $39.2 December 31, 2015. Under the Exchange Agreement, Total also received the following warrants, each with a five • A warrant to purchase 1,261,612 • A warrant to purchase 1,333,334 March 1, 2017, • Additionally, under the Exchange Agreement, Temasek received the following warrants, each with a ten • A warrant to purchase 978,525 • A warrant exercisable for that number of shares of the Company’s common stock equal to ( 1 may 133,334, 30.6% 69.4% 2 may 13.3% 86.7% • A warrant exercisable for that number of shares of the Company’s common stock equal to 58,690 133,334 58,690 The Temasek Exchange Warrant, the Temasek Funding Warrant and the Temasek R&D Warrant are referred to herein as the “Temasek Warrants” and the Temasek Warrants and the Total Warrants are hereinafter collectively referred to as the “Exchange Warrants”. In addition to the grant of the Exchange Warrants, a warrant issued by the Company to Temasek in October 2013 2013 66,667 2013 $0.01 In February May 2016, 164,169 May 2017, 1,125,755 As of March 1, 2017, not March 1, 2017 As of June 30, 2017, 2013 846,683 June 30, 2017. 1,289,924 June 30, 2017. $0.15 June 30, 2017. Maturity Treatment Agreement At the closing of the Exchange, the Company, Total and Temasek also entered into a Maturity Treatment Agreement, dated as of July 29, 2015, 2014 144A not not $10.0 2014 144A $25.0 $9.7 2014 144A $15.3 May 2017, 2014 144A no February 2016 On February 12, 2016 February 15, 2016, $18.0 $2.0 February 2016 171,429 19,048 $0.15 February 2016 $20.0 $16.0 February 2016 152,381 $2.0 February 2016 19,048 $2.0 February 2016 19,048 The February 2016 February 12, 2016, February 2016 13.50% May 15, 2017. May 2017, February 2016 February 2016 May 2017, first February 2016 May 15, 2017 November 15, 2017. As of June 30, 2017, February 2016 none February 2016 February 2016 $0.15 June 30, 2017. As of June 30, 2017, February 2016 $2.0 June 2016 On June 24, 2016, $5.0 June 2016 June 2016 13.50% June 2016 May 15, 2017. May 2017, June 2016 June 2016 October 2016 On October 21 October 27, 2016, $6.0 $8.5 October 2016 October 2016 October 2016 13.50% October 2016 May 15, 2017. May 2017, October 2016 October 2016 October 2016 May 2017, Salisbury Note In December 2016, $3.5 5% 13 January 1, 2017 ( 5% 5 January 2017, Nikko Note In December 2016, 7, $3.9 5% 13 January 1, 2017 ( 5% 5 first 10% $400,000 $100,000 January 1, 2017, February 1, 2017, March 1, 2017 April 1, 2017 fourth may Future minimum payments under the debt agreements as of June 30, 2017 Years ending December 31: Related Party Convertible Debt Convertible Debt Loans Related Party Loans Payable Credit Facility Total 2017 (remaining six months) $ 558 $ 4,123 $ 1,426 $ 2,487 $ 3,480 $ 12,074 2018 20,448 8,636 5,268 — 33,696 68,048 2019 34,913 68,097 2,665 — 2,577 108,252 2020 — — 2,559 — 2,500 5,059 2021 — — 2,451 — 27,396 29,847 Thereafter — — 4,057 — — 4,057 Total future minimum payments 55,919 80,856 18,426 2,487 69,649 227,337 Less: amount representing interest (1) (11,421 ) (26,385 ) (3,834 ) (487 ) (19,893 ) (62,020 ) Present value of minimum debt payments 44,498 54,471 14,592 2,000 49,756 165,317 Less: current portion (3,700 ) (1,517 ) (5,186 ) (2,000 ) (882 ) (13,285 ) Noncurrent portion of debt $ 40,798 $ 52,954 $ 9,406 $ — $ 48,874 $ 152,032 ( 1 Bill & Melinda Gates Foundation Investment (Mezzanine Equity) On May 10, 2016, 292,398 $17.10 $5.0 not 2017. third 10%. June 30, 2017, $5.0 not May 2017 On May 8, 2017 May 31, 2017, May 2017 22,140 17.38% $0.0001 70,904 17.38% $0.0001 $0.0001 14,768,380 May 2017 May 2017 May 2017 The May 2017 May 11, 2017 ( May 11 May 31, 2017, May 2017 $50.2 May 2017 $22,140,000, May 2017 $30,700,000 $40.2 $33.1 The May 2017 May 2017 may not July 31, 2017 may not one May 11 Series A Preferred Stock (Permanent Equity) Each share of Series A Preferred Stock has a stated value of $1,000 $17.25 not October 9, 2017, 90th Dividends, at a rate per year equal to 17.38% tenth October 15 April 15, October 15, 2017, tenth $1,738 $1,000 not first Unless and until converted into common stock in accordance with its terms, the Series A Preferred Stock has no In the event of a fundamental transaction, the holders of the Series A Preferred Stock will have the right to receive the consideration receivable as a result of such fundamental transaction by a holder of the number of shares of Common Stock for which the Series A Preferred Stock is convertible immediately prior to such fundamental transaction (without regard to whether such Series A Preferred Stock is convertible at such time), which amount shall be paid pari passu with all holders of Common Stock. Upon any liquidation, dissolution or winding-up of the Company, the holders of the Series A Preferred Stock shall be entitled to receive out of the assets of the Company the same amount that a holder of Common Stock would receive if the Series A Preferred Stock were fully converted to Common Stock immediately prior to such liquidation, dissolution or winding-up (without regard to whether such Series A Preferred Stock is convertible at such time), which amount shall be paid pari passu with all holders of Common Stock. Notwithstanding the foregoing, the holders (other than the Designated Holder (as defined below)) will not not 4.99% not 9.99%, not 61 The Series A Preferred Stock were offered and sold pursuant to a prospectus filed with the SEC on April 9, 2015 May 8, 2017, 3 No. 333 203216 April 15, 2015. On May 8, 2017, 17.38% The Series A preferred stock has been classified as permanent equity, as the Company controls all actions or events required to settle the Optional and Mandatory Conversion feature in shares. The make whole payment was determined to be an embedded derivative requiring bifurcation and separate recognition as a derivative liability recognized at its fair value as of the issuance date with subsequent changes in fair value recorded in earnings until the Series A preferred stock is converted into common stock and the make whole payment is paid or until the make whole payment is paid through declared dividends or cash. The Series A preferred stock also contains a beneficial conversion feature which has been recognized up to the amount of proceeds allocated to the preferred stock ( $0.6 $0.0 As of June 30, 2017, 18,840 $9.4 Series B Preferred Stock (Mezzanine Equity) The Series B Preferred Stock has substantially identical terms to the Series A Preferred Stock (as described above), except that the issuance of the shares of common stock issuable upon conversion of the Series B Preferred Stock or as payment of dividends or the Make-Whole Payment on the Series B Preferred Stock (or the Series B Conversion Shares) was initially subject to the Stockholder Approval (as defined below). The Series B Preferred Stock was accounted for as Mezzanine equity as the embedded conversion options are not The investors of the Series B Preferred Stock included related parties affiliated with certain members of the Company’s Board of Directors (or the Affiliated Investors). Foris exchanged an aggregate principal amount of $27.0 February 12, 2016, June 24, 2016 October 21, 2016, 30,728.589 May 2017 4,877,386 $2.0 February 15, 2016, 2,333.216 May 2017 370,404 $8.6 Certain investors of the Series B Preferred Stock included holders of certain of the Company’s existing indebtedness, including the 2014 144A 2015 144A $3.4 2014 144A $3.7 2015 144A May 2017 May 2017 May 11 $1.9 The remaining Series B preferred stock was purchased in exchange for cash proceeds of $30.7 no not A derivative liability has been recognized at fair value on the date of issuance for the make whole payment in the amount of $34.7 June 30, 2017 $0.8 May 2017 Pursuant to the May 2017 $7.80 June 30, 2017, 50% 7,384,190 $9.30 June 30, 2017, 7,384,190 three In addition, the Company issued to each investor a warrant, with an exercise price of $0.0015 June 30, 2017 ( three $6.30 May 2017 The exercise of the May 2017 May 2017 five May 2017 The Cash Warrants are freestanding financial instruments that are accounted for as derivative liabilities and recognized at their fair value on the date of issuance of $39.5 May 2022. The full-ratchet anti-dilution protection of the Cash Warrants are also freestanding financial instruments that have been accounted for as derivative liabilities and recognized at their fair value on the date of issuance of $4.4 May 2020. Stockholder Approval Pursuant to the May 2017 May 2017 May 2017 July 10, 2017, July 7, 2017. Registration Rights Pursuant to the May 2017 30 3 not 3 May 2017 181 no May 2017 May 2017 144 August [4], 2017, 3 May 2017 May 2017 Stockholder Agreement In connection with the May 2017 May 11, 2017, one 25,000 3,968,116 May 2017 $25,000,000. one May 18, 2017, no 4.5% not 60 2018. Pursuant to the Stockholder Agreement, the Designated Holder agreed not May 2017 May 2017 one third first May 2017 May 2017 three no not, 33% May 2017 not 13 3 1934 Pursuant to the Stockholder Agreement, the Company and the Designated Holder agreed to negotiate in good faith during the 90 no $25 no $30 90 second not 90 December 31, 2017, ( first $5 not 14, Series C Preferred Stock Exchange In connection with the transactions contemplated by the May 2017 May 8, 2017, May 2017 1,394,706 20,921 $0.0001 not May 2017 May 11, 2017. Each share of Series C Preferred Stock has a stated value of $1,000 $15 The Series C Preferred Stock is entitled to participate with the common stock on an as-converted basis with respect to any dividends or other distributions to holders of common stock. The Series C Preferred Stock shall vote together as one In the event of a fundamental transaction, the holders of the Series C Preferred Stock will have the right to receive the consideration receivable as a result of such fundamental transaction by a holder of the number of shares of common stock for which the Series C Preferred Stock is convertible immediately prior to such fundamental transaction (without regard to whether such Series C Preferred Stock is convertible at such time), which amount shall be paid pari passu with all holders of common stock. Upon any liquidation, dissolution or winding-up of the Company, the holders of the Series C Preferred stock shall be entitled to receive out of the assets of the Company an amount equal to the greater of (i) the par value of each share of Series C Preferred Stock, plus any accrued and unpaid dividends or other amounts due on such Series C Preferred Stock, prior to any distribution or payment to the holders of common stock or (ii) the amount that a holder would receive if the Series C Preferred Stock were fully converted to common stock immediately prior to such liquidation, dissolution or winding-up (without regard to whether such Series C Preferred Stock is convertible at such time), which amount shall be paid pari passu with all holders of Common Stock. The shares of Series C Preferred Stock automatically converted to common stock on June 6, 2017 15:1 no

Note 6 - Commitments and Contin

Note 6 - Commitments and Contingencies	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Commitments Contingencies and Guarantees [Text Block]	6. Lease Obligations The Company leases certain facilities and finances certain equipment under operating and capital leases, respectively. Operating leases include leased facilities and capital leases include leased equipment (see Note 4, February 2031. $1.4 $1.4 three June 30, 2017 2016, $2.8 $2.7 six June 30, 2017 2016, Future minimum payments under the Company's lease obligations as of June 30, 2017 Years ending December 31: Capital Operating Total Lease 2017 (remaining six months) $ 530 $ 3,406 $ 3,936 2018 106 6,889 6,995 2019 22 6,776 6,798 2020 — 7,006 7,006 2021 — 7,242 7,242 Thereafter — 10,958 10,958 Total future minimum payments $ 658 $ 42,277 $ 42,935 Less: amount representing interest (27 ) Present value of minimum lease payments 631 Less: current portion (598 ) Long-term portion $ 33 Guarantor Arrangements The Company has agreements whereby it indemnifies its officers and directors for certain events or occurrences while the officers or directors are serving in their official capacities. The indemnification period remains enforceable for the officer's or director’s lifetime. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is unlimited; however, the Company has a director and officer insurance policy that limits its exposure and enables the Company to recover a portion of any future payments. As a result of its insurance policy coverage, the Company believes the estimated fair value of these indemnification agreements is minimal. Accordingly, the Company had no June 30, 2017 December 31, 2016. Purchase Obligations As of June 30, 2017 December 31, 2016, $0.9 $0.8 $0.6 $0.6 Production Cost Commitment As of June 30, 2017, not three six June 30, 2017 three $10 Other Matters Certain conditions may may one may If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company's financial statements. If the assessment indicates that a potential material loss contingency is not not The Company has levied indirect taxes on sugarcane-based biodiesel sales by Amyris Brasil to customers in Brazil based on advice from external legal counsel. In the absence of definitive rulings from the Brazilian tax authorities on the appropriate indirect tax rate to be applied to such product sales, the actual indirect rate to be applied to such sales could differ from the rate we levied. In April 2017, March 2, 2017 April 17, 2017. March 2, 2017 12b 25 April 3, 2017. In June 2017, Gutierrez v John G. Melo et al No. 665782, not The Company is subject to disputes and claims that arise or have arisen in the ordinary course of business and that have not not may not one

Note 7 - Joint Ventures and Non

Note 7 - Joint Ventures and Noncontrolling Interest	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Equity Method Investments and Joint Ventures Disclosure [Text Block]	7. Aprinnova JV The Company is a 50% The table below reflects the carrying amount of the Aprinnova JV's assets and liabilities, for which the Company is the primary beneficiary at June 30, 2017: (In thousands) June 30, 2017 December 31, 2016 Assets $ 32,541 $ 30,778 Liabilities 2,221 333 The change in the Company's noncontrolling interest in Aprinnova JV for the six June 30, 2017 2016, 2017 2016 Balance at January 1 $ 937 $ — Acquisition of noncontrolling interest — 114 Balance at June 30 $ 937 $ 114

Note 8 - Significant Agreements

Note 8 - Significant Agreements	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Collaborative Arrangement Disclosure [Text Block]	8. Research and Development Activities Firmenich Collaboration Agreement In March 2013, November 2010 10 3 twelve The Firmenich Collaboration Agreement provided for annual, up-front funding to the Company by Firmenich of $10.0 first three $10.0 March 2013, 2014 2015. $5.0 four June 2017, four $2.1 $1.3 three June 30, 2017 2016, $3.2 $4.3 six June 30, 2017 2016, not Under the Firmenich Collaboration Agreement, the parties agreed to jointly select target compounds, subject to final approval of compound specifications by Firmenich. During the development phase, the Company would be required to provide labor, intellectual property and technology infrastructure and Firmenich would be required to contribute downstream polishing expertise and market access. The Firmenich Collaboration Agreement provides that the Company will own research and development and strain engineering intellectual property, and Firmenich will own blending and, if applicable, chemical conversion intellectual property. Under certain circumstances, such as the Company’s insolvency, Firmenich would gain expanded access to the Company’s intellectual property. The Firmenich Collaboration Agreement contemplates that, following development of flavors and fragrances compounds, the Company will manufacture the initial target molecules for the compounds and Firmenich will perform any required downstream polishing and distribution, sales and marketing. The Firmenich Collaboration Agreement provides that the parties will mutually agree on a supply price for each compound developed under the agreement and, subject to certain exceptions, will share product margins from sales of each such compound on a 70/30 70% $15.0 50/50. one $2.5 not June 30, 2017. In September 2014, $0.9 $2.6 three June 30, 2017 2016, $2.1 $4.6 six June 30, 2017 2016, In December 2016, third ten third 2016 Kuraray Collaboration Agreement In July 2011, March 2014, two $4.0 two $2.0 first April 30, 2014 second April 30, 2015. March 2015, December 31, 2016 second $2.0 March 31, 2015. November 2016 #3 December 31, 2018 $1.0 two $500,000 January 15, 2017 January 15, 2018, Under this agreement, the Company recognized (i) collaboration revenues of $0.1 $0.4 three June 30, 2017 2016, $0.3 $0.8 six June 30, 2017 2016, $1.9 $0.2 three June 30, 2017 2016, $3.6 $0.2 six June 30, 2017 2016, DARPA Technology Investment Agreement In September 2015, 2015 five 2015 2015 2015 2015 $35.0 4 $15.5 four may, 2015 not The Company recognized collaboration revenues of $ 4.7 $2.3 three June 30, 2017 2016, $5.7 $3.5 six June 30, 2017 2016, Nenter Agreements In April 2016, six 2017, $2.4 December 31, 2020 5 no July 1, 2020, The Company recognized revenues from product sales under the Nenter Supply Agreement of $6.6 zero three June 30, 2017 2016, $8.9 $0.03 six June 30, 2017 2016, In October 2016, May 2017 5, May 8, 2017, October 26, 2016, $2.5 June 22, 2017. 40 June 28, 2017. Givaudan Agreements In June 2016, $12.0 $3.0 June 30, 2016. $3.0 June 2016, December 2016 June 2017, Pursuant to the Givaudan Collaboration Agreement, the Company agreed to grant to Givaudan an exclusive license to the intellectual property that the Company generates under the agreement. Such license will include the rights to make, use and sell compounds in the active cosmetics and flavors fields, and is subject to certain ‘claw back’ rights by the Company if a compound is not Subject to certain rights granted to a third not third 2 The Company recognized collaboration revenues under the Givaudan Collaboration Agreement of $1.5 $0 three June 30, 2017 2016, $3.0 $0 six June 30, 2017 2016, Ginkgo Initial Strategic Partnership Agreement and Collaboration Agreement In June 2016, $20.0 two ten first $15.0 July 25, 2016. second $5.0 not June 30, 2017, no In addition, pursuant to the Initial Ginkgo Agreement, (i) the Company and Ginkgo agreed to pursue the negotiation and execution of a detailed definitive partnership and license agreement setting forth the terms of a commercial partnership and collaboration arrangement between the parties (Ginkgo Collaboration), (ii) the Company agreed to issue to Ginkgo an option to purchase 333,334 $7.50, one October 31, 2016 x 5, On August 6, 2016, 333,334 $7.50 one On September 30, 2016, third not March 30, 2017, $5.0 second not June 30, 2017, no Under the Ginkgo Collaboration Agreement, subject to certain exceptions, including excluded or refused products and cost savings initiatives, the profit on the sale of products subject to the Ginkgo Collaboration Agreement as well as cost-sharing, milestone and “value-creation” payments associated with the development and production of such products will be shared equally between the parties. The parties also agreed to provide each other with a license and other rights to certain intellectual property necessary to support the development and manufacture of the products under the Ginkgo Collaboration, and also to provide each other with access to certain other intellectual property useful in connection with the activities to be undertaken under the Ginkgo Collaboration Agreement, subject to certain carve-outs. The initial term of the Ginkgo Collaboration Agreement is three one not 90 18 30 In April 2017, $3 5, The Company recognized zero zero three June 30, 2017 June 30, 2016, zero zero six June 30, 2017 June 30, 2016, June 30, 2017, $1.5 Blue California Agreements In December 2016, $10 March 31, 2017, April 17, 2017, April 2017, one $10 April 21, 2017, 850,115 The Company recognized revenues of $2.7 $0 three June 30, 2017 2016, $2.7 $0 six June 30, 2017 2016, Financing Agreements At Market Issuance Sales Agreement On March 8, 2016, may $50.0 3 No. 333 203216 April 15, 2015. 415 one may not 3.0% no During the six June 30, 2017, not $50.0 See Note 14, June 30, 2017.

Note 9 - Goodwill and Intangibl

Note 9 - Goodwill and Intangible Assets	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Goodwill and Intangible Assets Disclosure [Text Block]	9. The following table presents the components of the Company's intangible assets (in thousands): June 30, 2017 December 31, 2016 Useful Life in Years Gross Carrying Amount Accumulated Amortization Net Carrying Value Gross Carrying Amount Accumulated Amortization Net Carrying Value In-process research and development Indefinite $ 8,560 $ (8,560 ) $ — $ 8,560 $ (8,560 ) $ — Acquired licenses and permits 2 772 (772 ) — 772 (772 ) — Goodwill Indefinite 560 — 560 560 — 560 $ 9,892 $ (9,332 ) $ 560 $ 9,892 $ (9,332 ) $ 560 The Company has a single reportable segment. Consequently, all of the Company's goodwill is attributable to that single reportable segment.

Note 10 - Stock-based Compensat

Note 10 - Stock-based Compensation	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	10. The Company’s stock option activity and related information for the six June 30, 2017 Number Weighted- Weighted- Aggregate (in thousands) Outstanding - December 31, 2016 875,021 $ 55.20 Options granted 192,569 $ 6.94 — $ — Options exercised (133 ) $ 4.20 — $ — Options forfeited (70,182 ) $ 27.03 — $ — Outstanding - June 30, 2017 997,275 $ 47.87 7.01 $ 440 Vested and expected to vest after June 30, 2017 895,140 $ 51.99 6.76 $ 310 Exercisable at June 30, 2017 539,738 $ 76.14 5.36 $ — The Company’s restricted stock units (or "RSUs") and restricted stock activity and related information for the six June 30, 2017 RSUs Weighted- Weighted Average Outstanding - December 31, 2016 454,923 $ 17.48 Awarded 354,117 $ 6.74 — Vested (106,833 ) $ 22.33 — Forfeited (35,871 ) $ 13.76 — Outstanding - June 30, 2017 666,336 $ 11.20 1.64 Expected to vest after June 30, 2017 501,550 $ 11.56 1.45 Stock-based Compensation Expense Stock-based compensation expense related to options and restricted stock units granted to employees and non-employees was allocated to research and development expense and sales, general and administrative expense as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2017 2016 2017 2016 Research and development $ 441 $ 485 $ 925 $ 976 Sales, general and administrative 597 1,304 1,759 2,864 Total stock-based compensation expense $ 1,038 $ 1,789 $ 2,684 $ 3,840 As of June 30, 2017, $8.5 2.9 Stock-based compensation expense for RSUs is measured based on the closing fair market value of the Company's common stock on the date of grant. Stock-based compensation expense for stock options and employee stock purchase plan rights is estimated at the grant date and offering date, respectively, based on their fair-value using the Black-Scholes option pricing model. The fair value of employee stock options is being amortized on a straight-line basis over the requisite service period of the awards. The fair value of employee stock options was estimated using the following weighted-average assumptions: Three Months Ended June 30, Six Months Ended June 30, 2017 2016 2017 2016 Expected dividend yield — % — % — % — % Risk-free interest rate 1.82 % 1.4 % 1.82 % 1.4 % Expected term (in years) 5.38 6.16 5.38 6.16 Expected volatility 85.7 % 72.5 % 85.7 % 72.5 %

Note 11 - Related Party Transac

Note 11 - Related Party Transactions	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	11. Related Party Financings See Note 5, three six June 30, 2017. 14, June 30, 2017. As of June 30, 2017 December 31, 2016, $46.3 $72.4 $5.1 $6.7 The fair value of the derivative liability in connection with the related party convertible notes and preferred stock as of June 30, 2017 December 31, 2016 $41.0 $0.8 three June 30, 2017 2016, $22.3 $3.9 six June 30, 2017 2016, $20.0 $8.4 3, Related Party Revenues During the three six June 30, 2017 2016, $0.1 June 30, 2017 December 31, 2016, $0.6 $0.8 Joint Venture with Cosan and American Refining Group In June 2017, $60,000 Pilot Plant Agreements with Total The Company and Total are parties to two five April 4, 2014 June 30, 2017 December 31, 2016, $1.4 $1.8

Note 12 - Income Taxes

Note 12 - Income Taxes	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Income Tax Disclosure [Text Block]	12. The Company recorded income tax provisions of $0.3 $0.1 three June 30, 2017 2016, $0.3 $0.3 six June 30, 2017 2016, no

Note 13 - Net Loss Per Share At

Note 13 - Net Loss Per Share Attributable to Common Stockholders	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Earnings Per Share [Text Block]	13. Basic net loss per share attributable to common stockholders is computed by dividing the Company’s net loss attributable to Amyris, Inc. common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share attributable to common stockholders is computed by giving effect to all potentially dilutive securities, including stock options, restricted stock units, common stock warrants and convertible promissory notes using the treasury stock method or the as-converted method, as applicable. For the three six June 30, 2017, The following table presents the calculation of basic and diluted net loss per share attributable to common stockholders (in thousands, except share and per share amounts): Three Months Ended June 30, Six Months Ended June 30, 2017 2016 2017 2016 Numerator: Net income (loss) $ 620 $ (13,566 ) $ (36,751 ) $ (28,874 ) Less deemed dividend (capital distribution to related parties) (8,648 ) — (8,648 ) — Less deemed dividend related to beneficial conversion feature on Series A preferred stock (562 ) — (562 ) — Less cumulative dividends on Series A and Series B preferred stock (1,675 ) — (1,675 ) — Net loss attributable to Amyris, Inc. common stockholders, basic (10,265 ) (13,566 ) (47,636 ) (28,874 ) Interest on convertible debt — 1,591 — 3,501 Accretion of debt discount — 1,846 — 3,479 Loss (gain) from change in fair value of derivative instruments — (19,116 ) — (37,803 ) Net loss attributable to Amyris, Inc. common stockholders, diluted $ (10,265 ) $ (29,245 ) $ (47,636 ) $ (59,697 ) Denominator: Weighted-average shares of common stock outstanding used in computing net loss per share of common stock, basic 23,155,874 14,874,135 21,226,013 14,426,247 Basic loss per share $ (0.44 ) $ (0.91 ) $ (2.24 ) $ (2.00 ) Weighted-average shares of common stock outstanding 23,155,874 14,874,135 21,226,013 14,426,247 Effect of dilutive convertible promissory notes — 2,652,275 — 2,827,714 Weighted-average common stock equivalents used in computing net loss per share of common stock, diluted 23,155,874 17,526,410 21,226,013 17,253,961 Diluted loss per share $ (0.44 ) $ (1.67 ) $ (2.24 ) $ (3.46 ) The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share of common stock because including them would have been anti-dilutive: Three Months Ended June 30, Six Months Ended June 30, 2017 2016 2017 2016 Period-end stock options to purchase common stock 997,275 948,603 997,275 948,603 Convertible promissory notes (1) 6,270,734 4,489,743 6,270,734 4,489,743 Period-end common stock warrants 16,871,700 193,429 16,871,700 193,429 Period-end restricted stock units 666,336 520,602 666,336 520,602 Total 24,806,045 6,152,377 24,806,045 6,152,377 ______________ ( 1 The potentially dilutive effect of convertible promissory notes was computed based on conversion ratios in effect as of the respective period end dates. A portion of the convertible promissory notes issued carries a provision for a reduction in conversion price under certain circumstances, which could potentially increase the dilutive shares outstanding. Another portion of the convertible promissory notes issued carries a provision for an increase in the conversion rate under certain circumstances, which could also potentially increase the dilutive shares outstanding.

Note 14 - Subsequent Events

Note 14 - Subsequent Events	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Subsequent Events [Text Block]	14. August 2017 DSM Purchase Agreement On August 2, 2017, 25,000 August 2017 3,968,116 August 2017 August 2017 August 2017 4 2 August 2017 On August 7, 2017, 25,000 August 2017 $24.8 August 7, 2017, August 2017 5, The DSM Purchase Agreement includes customary representations, warranties and covenants of the parties. In addition, the Company, subject to certain exceptions, (i) may not October 31, 2017, ( may not May 11, 2018 may not DSM Warrants At the August 2017 $6.30 3,968,116 August 2017 August 2017 three In addition, at the DSM Closing, the Company issued to DSM a warrant, with an exercise price of $0.0001 August 2017 $6.30 August 2017 $0.10 The effectiveness of the anti-dilution adjustment provision of the August 2017 August 2017 August 2017 August 2017 five August 2017 The August 2017 4 2 Registration Pursuant to the DSM Purchase Agreement, the Company on August 4, 2017 3 August 2017 August 2017 Amended and Restated Stockholder Agreement In connection with the August 2017 May 11, 2017 two one 10% no 4.5% August 2017 Following the August 2017 not 90 August 2017 first August 2017 $5 not $25 Vivo Purchase Agreement On August 2, 2017, August 2017 August 2017 2,826,711 $4.26 12,958 $0.0001 August 2017 5,575,118 August 2017 August 2017 August 2017 4 2 August 2017 On August 3, 2017, 2,826,711 12,958 August 2017 $24.8 August 3, 2017, The August 2017 August 2017 may not Series D Preferred Stock Each share of Series D Preferred Stock has a stated value of $1,000 August 2017 $4.26 Prior to declaring any dividend or other distribution of its assets to holders of common stock, the Company shall first $0.0001 Unless and until converted into common stock in accordance with its terms, the Series D Preferred Stock has no In the event of a Fundamental Transaction, the holders of the Series D Preferred Stock will have the right to receive the consideration receivable as a result of such Fundamental Transaction by a holder of the number of shares of common stock for which the Series D Preferred Stock is convertible immediately prior to such Fundamental Transaction (without regard to whether such Series D Preferred Stock is convertible at such time), which amount shall be paid pari passu with all holders of common stock. A Fundamental Transaction is defined in the Certificate of Designation of Preferences, Rights and Limitations relating to the Series D Preferred Stock as any of the following: (i) merger with or consolidation into another legal entity; (ii) sale, lease, license, assignment, transfer or other disposition of all or substantially all of the Company’s assets in one 50% 50% Upon any liquidation, dissolution or winding-up of the Company, the holders of the Series D Preferred Stock shall be entitled to receive out of the assets of the Company the same amount that a holder of Common Stock would receive if the Series D Preferred Stock were fully converted to common stock immediately prior to such liquidation, dissolution or winding-up (without regard to whether such Series D Preferred Stock is convertible at such time) , which amount shall be paid pari passu with all holders of common stock. Notwithstanding the foregoing, the holders will not not 9.99% August 2017 may August 2017 not 61st no not On August 3, 2017, Vivo Warrants At the August 2017 $6.39 5,575,118 August 2017 August 2017 three August August 2017 In addition, at the August 2017 $0.0001 August 2017 $4.26 The effectiveness of the anti-dilution adjustment provisions of the August 2017 August 2017 August 2017 August 2017 five August 2017 August 2017 August 2017 The August 2017 4 2 Vivo Stockholder Agreement In connection with the August 2017 one no 4.5% 4.5% Pursuant to the Vivo Stockholder Agreement, Vivo will agree not August 2017 August 2017 one August 2017 third first August 2017 three August 2017 three no not, 33% August 2017 not 13 3 1934 In addition, the Company has agreed to register, via one August 2017 August 2017 no November 7, 2017, no December 22, 2017. may three 25% Stockholder Approval Pursuant to the August 2017 may August 2017 August 2017 August 2017 2018 August 2017 may, 90 2018 August 2017 not August 2017 first four August 2017 August 2017 August 2017 August 2017 no August 2017 August 2017 may not August 2017 August 2017 August 2017

Significant Accounting Policies

Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2017
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation and Principles of Consolidation The consolidated financial statements include the results of wholly-owned and partially-owned subsidiaries in which the Company has a controlling interest with all significant intercompany accounts and transactions eliminated in consolidation.
Unaudited Interim Financial Information [Policy Text Block]	Unaudited Interim Financial Information The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (or U.S. GAAP) for interim financial information and Article 10 X not June 30, 2017, three six June 30, 2017 2016, six June 30, 2017 2016. December 31, 2016 not 10 10 December 31, 2016.
Reverse Stock Split [Policy Text Block]	Reverse Stock Split On June 5, 2017, 1 15 $0.0001 500,000,000 250,000,000. not first first may The par value, number of shares outstanding and number of authorized shares of preferred stock were not
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the periods reported. Actual results could differ from these estimates, and such differences may The accompanying interim condensed consolidated financial statements and related disclosures are unaudited, have been prepared on the same basis as the annual consolidated financial statements, except for the impact of adoption of certain accounting standards as described below, and in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for a fair statement of the results of operations for the periods presented. In the six June 30, 2017 • ASU 2015 11, Inventory (Topic 330 • ASU 2016 06, Derivatives and Hedging (Topic 815 • ASU 2016 09, Compensation—Stock Compensation (Topic 718 None
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements Revenue Recognition May 2014, 2014 09, 606 , Revenue from Contracts with Customers 605, Revenue Recognition 2015 2016, first 2018. may first 2018. may not Financial Instruments January 2016, 2016 01, Financial Instruments-Overall (Subtopic 825 10 first 2018. 2016 01 not Leases February 2016, 2016 02, Leases (Topic 842 first 2019 Credit Losses of Financial Instruments June 2016, 2016 13, Financial Instruments-Credit Losses (Topic 326 2016 13 first 2020 Classification of Cash Flow Elements August 2016, 2016 15, Statement of Cash Flows (Topic 230 first 2018 Restricted Cash in Statement of Cash Flows November 2016, 2016 18, Statement of Cash Flows (Topic 230 first 2018 2016 18 Derecognition of Nonfinancial Assets February 2017, 2017 05, Other Income—Gains and Losses from the Derecognition of Nonfinancial Assets (Subtopic 610 20 606 not 1 not 2 not first 2018 When Changes to Share-based Payment Awards Must Be Accounted for as Modifications May 2017, 2017 09, Compensation—Stock Compensation (Topic 718 not first 2018

Note 3 - Fair Value of Financ24

Note 3 - Fair Value of Financial Instruments (Tables)	6 Months Ended
	Jun. 30, 2017
Notes Tables
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	Level 1 Level 2 Level 3 Balance as of Financial Assets Money market funds $ 5,078 $ — $ — $ 5,078 Certificates of deposit 5,371 — — 5,371 Total financial assets $ 10,449 $ — $ — $ 10,449 Financial Liabilities Compound embedded derivative liability $ — $ — $ 56,222 $ 56,222 Currency interest rate swap derivative liability — — 2,384 2,384 Total financial liabilities $ — $ — $ 58,606 $ 58,606 Level 1 Level 2 Level 3 Balance as of Financial Assets Money market funds $ 1,549 $ — $ — $ 1,549 Certificates of deposit 1,373 — — 1,373 Total financial assets $ 2,922 $ — $ — $ 2,922 Financial Liabilities Compound embedded derivative liability $ — $ — $ 4,135 $ 4,135 Currency interest rate swap derivative liability — — 3,343 3,343 Total financial liabilities $ — $ — $ 7,478 $ 7,478
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	2017 Balance at January 1 $ 4,135 Gain from change in fair value of derivative liabilities (in statements of operations) (32,210 ) Additions 93,675 Derecognition on extinguishment or conversion (9,378 ) Balance at June 30 $ 56,222
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table Text Block]	June 30, 2017 May 11, 2017 December 31, 2016 Risk-free interest rate 1.29% - 1.93% 1.93% 0.55% - 1.31% Risk-adjusted yields 4.50% - 28.93% — 12.80% - 22.93% Stock-price volatility 45% - 80% 80% 45% Probability of change in control 5% 5% 5% Stock price $3.18 $4.95 $0.73 Credit spread 3.15% - 27.57% — 11.59% - 21.64% Estimated conversion dates 2017 - 2022 2017 - 2022 2017 - 2019
Derivative Instruments, Gain (Loss) [Table Text Block]	Three Months Ended June 30, Six Months Ended June 30, Type of Derivative Contract 2017 2016 2017 2016 Compound embedded derivative liabilities $ 35,814 $ 19,659 $ 36,315 $ 40,492 Currency interest rate swaps (39 ) 1,275 1,799 2,120 Total gain from change in fair value of derivative instruments $ 35,775 $ 20,934 $ 38,114 $ 42,612

Note 4 - Balance Sheet Compon25

Note 4 - Balance Sheet Components (Tables)	6 Months Ended
	Jun. 30, 2017
Notes Tables
Schedule of Inventory, Current [Table Text Block]	June 30, December 31, Raw materials $ 2,937 $ 3,159 Work-in-process 1,379 1,848 Finished goods 1,413 1,206 Inventories $ 5,729 $ 6,213
Property, Plant and Equipment [Table Text Block]	June 30, December 31, 2016 Machinery and equipment $ 84,785 $ 82,688 Leasehold improvements 38,770 38,785 Computers and software 9,619 9,585 Buildings 4,630 4,699 Furniture and office equipment 2,324 2,333 Vehicles 133 164 Land 460 460 Construction in progress 367 2,216 141,088 140,930 Less: accumulated depreciation and amortization (91,785 ) (87,195 ) Property, plant and equipment, net $ 49,303 $ 53,735
Schedule of Other Assets, Noncurrent [Table Text Block]	June 30, December 31, Recoverable taxes from Brazilian government entities $ 15,443 $ 13,723 Cost-method investment 3,233 — Deposits on property and equipment, including taxes 909 291 Other 1,198 1,450 Total other assets $ 20,783 $ 15,464
Schedule of Accrued and Other Current Liabilities [Table Text Block]	June 30, December 31, Withholding tax related to conversion of related party notes $ 1,370 $ 1,370 Professional services 5,943 6,876 SMA relocation accrual 3,587 3,641 Accrued interest 4,133 4,847 Tax-related liabilities 2,741 2,610 Accrued vacation 2,274 2,034 Payroll and related expenses 3,512 4,310 Deferred rent, current portion 1,122 1,111 Contractual obligations to contract manufacturers 2,698 — Other 1,895 2,389 Total accrued and other current liabilities $ 29,275 $ 29,188

Note 5 - Debt and Mezzanine E26

Note 5 - Debt and Mezzanine Equity (Tables)	6 Months Ended
	Jun. 30, 2017
Notes Tables
Schedule of Debt [Table Text Block]	June 30, 2017 December 31, 2016 Senior secured loan facility $ 27,999 $ 27,658 BNDES credit facility 577 1,172 FINEP credit facility 534 696 Guanfu credit facility 20,645 19,564 Total credit facilities 49,755 49,090 Convertible notes 54,471 78,981 Loans payable 14,592 26,527 Related party convertible notes 44,499 42,754 Related party loan payable 2,000 29,691 Total debt 165,317 227,043 Less: current portion (13,285 ) (59,155 ) Long-term debt, net of current portion $ 152,032 $ 167,888 Mezzanine equity Contingently redeemable common stock $ 5,000 $ 5,000 Convertible preferred stock $ 12,830 $ —
Schedule of Long-term Debt Instruments [Table Text Block]	Years ending December 31: Related Party Convertible Debt Convertible Debt Loans Related Party Loans Payable Credit Facility Total 2017 (remaining six months) $ 558 $ 4,123 $ 1,426 $ 2,487 $ 3,480 $ 12,074 2018 20,448 8,636 5,268 — 33,696 68,048 2019 34,913 68,097 2,665 — 2,577 108,252 2020 — — 2,559 — 2,500 5,059 2021 — — 2,451 — 27,396 29,847 Thereafter — — 4,057 — — 4,057 Total future minimum payments 55,919 80,856 18,426 2,487 69,649 227,337 Less: amount representing interest (1) (11,421 ) (26,385 ) (3,834 ) (487 ) (19,893 ) (62,020 ) Present value of minimum debt payments 44,498 54,471 14,592 2,000 49,756 165,317 Less: current portion (3,700 ) (1,517 ) (5,186 ) (2,000 ) (882 ) (13,285 ) Noncurrent portion of debt $ 40,798 $ 52,954 $ 9,406 $ — $ 48,874 $ 152,032

Note 6 - Commitments and Cont27

Note 6 - Commitments and Contingencies (Tables)	6 Months Ended
	Jun. 30, 2017
Notes Tables
Schedule Of Future Minimum Payments For Lease Obligations [Table Text Block]	Years ending December 31: Capital Operating Total Lease 2017 (remaining six months) $ 530 $ 3,406 $ 3,936 2018 106 6,889 6,995 2019 22 6,776 6,798 2020 — 7,006 7,006 2021 — 7,242 7,242 Thereafter — 10,958 10,958 Total future minimum payments $ 658 $ 42,277 $ 42,935 Less: amount representing interest (27 ) Present value of minimum lease payments 631 Less: current portion (598 ) Long-term portion $ 33

Note 7 - Joint Ventures and N28

Note 7 - Joint Ventures and Noncontrolling Interest (Tables)	6 Months Ended
	Jun. 30, 2017
Notes Tables
Schedule of Variable Interest Entities [Table Text Block]	(In thousands) June 30, 2017 December 31, 2016 Assets $ 32,541 $ 30,778 Liabilities 2,221 333
Noncontrolling Interest [Table Text Block]	2017 2016 Balance at January 1 $ 937 $ — Acquisition of noncontrolling interest — 114 Balance at June 30 $ 937 $ 114

Note 9 - Goodwill and Intangi29

Note 9 - Goodwill and Intangible Assets (Tables)	6 Months Ended
	Jun. 30, 2017
Notes Tables
Schedule of Intangible Assets and Goodwill [Table Text Block]	June 30, 2017 December 31, 2016 Useful Life in Years Gross Carrying Amount Accumulated Amortization Net Carrying Value Gross Carrying Amount Accumulated Amortization Net Carrying Value In-process research and development Indefinite $ 8,560 $ (8,560 ) $ — $ 8,560 $ (8,560 ) $ — Acquired licenses and permits 2 772 (772 ) — 772 (772 ) — Goodwill Indefinite 560 — 560 560 — 560 $ 9,892 $ (9,332 ) $ 560 $ 9,892 $ (9,332 ) $ 560

Note 10 - Stock-based Compens30

Note 10 - Stock-based Compensation (Tables)	6 Months Ended
	Jun. 30, 2017
Notes Tables
Schedule of Share-based Compensation, Stock Options and Stock Appreciation Rights Award Activity [Table Text Block]	Number Weighted- Weighted- Aggregate (in thousands) Outstanding - December 31, 2016 875,021 $ 55.20 Options granted 192,569 $ 6.94 — $ — Options exercised (133 ) $ 4.20 — $ — Options forfeited (70,182 ) $ 27.03 — $ — Outstanding - June 30, 2017 997,275 $ 47.87 7.01 $ 440 Vested and expected to vest after June 30, 2017 895,140 $ 51.99 6.76 $ 310 Exercisable at June 30, 2017 539,738 $ 76.14 5.36 $ —
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block]	RSUs Weighted- Weighted Average Outstanding - December 31, 2016 454,923 $ 17.48 Awarded 354,117 $ 6.74 — Vested (106,833 ) $ 22.33 — Forfeited (35,871 ) $ 13.76 — Outstanding - June 30, 2017 666,336 $ 11.20 1.64 Expected to vest after June 30, 2017 501,550 $ 11.56 1.45
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	Three Months Ended June 30, Six Months Ended June 30, 2017 2016 2017 2016 Research and development $ 441 $ 485 $ 925 $ 976 Sales, general and administrative 597 1,304 1,759 2,864 Total stock-based compensation expense $ 1,038 $ 1,789 $ 2,684 $ 3,840
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Three Months Ended June 30, Six Months Ended June 30, 2017 2016 2017 2016 Expected dividend yield — % — % — % — % Risk-free interest rate 1.82 % 1.4 % 1.82 % 1.4 % Expected term (in years) 5.38 6.16 5.38 6.16 Expected volatility 85.7 % 72.5 % 85.7 % 72.5 %

Note 13 - Net Loss Per Share 31

Note 13 - Net Loss Per Share Attributable to Common Stockholders (Tables)	6 Months Ended
	Jun. 30, 2017
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months Ended June 30, Six Months Ended June 30, 2017 2016 2017 2016 Numerator: Net income (loss) $ 620 $ (13,566 ) $ (36,751 ) $ (28,874 ) Less deemed dividend (capital distribution to related parties) (8,648 ) — (8,648 ) — Less deemed dividend related to beneficial conversion feature on Series A preferred stock (562 ) — (562 ) — Less cumulative dividends on Series A and Series B preferred stock (1,675 ) — (1,675 ) — Net loss attributable to Amyris, Inc. common stockholders, basic (10,265 ) (13,566 ) (47,636 ) (28,874 ) Interest on convertible debt — 1,591 — 3,501 Accretion of debt discount — 1,846 — 3,479 Loss (gain) from change in fair value of derivative instruments — (19,116 ) — (37,803 ) Net loss attributable to Amyris, Inc. common stockholders, diluted $ (10,265 ) $ (29,245 ) $ (47,636 ) $ (59,697 ) Denominator: Weighted-average shares of common stock outstanding used in computing net loss per share of common stock, basic 23,155,874 14,874,135 21,226,013 14,426,247 Basic loss per share $ (0.44 ) $ (0.91 ) $ (2.24 ) $ (2.00 ) Weighted-average shares of common stock outstanding 23,155,874 14,874,135 21,226,013 14,426,247 Effect of dilutive convertible promissory notes — 2,652,275 — 2,827,714 Weighted-average common stock equivalents used in computing net loss per share of common stock, diluted 23,155,874 17,526,410 21,226,013 17,253,961 Diluted loss per share $ (0.44 ) $ (1.67 ) $ (2.24 ) $ (3.46 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Three Months Ended June 30, Six Months Ended June 30, 2017 2016 2017 2016 Period-end stock options to purchase common stock 997,275 948,603 997,275 948,603 Convertible promissory notes (1) 6,270,734 4,489,743 6,270,734 4,489,743 Period-end common stock warrants 16,871,700 193,429 16,871,700 193,429 Period-end restricted stock units 666,336 520,602 666,336 520,602 Total 24,806,045 6,152,377 24,806,045 6,152,377

Note 1 - The Company (Details T

Note 1 - The Company (Details Textual) - USD ($) $ in Thousands	1 Months Ended
	Aug. 31, 2017	Jun. 30, 2017	Dec. 31, 2016
Working Capital		$ (21,800)
Retained Earnings (Accumulated Deficit)		(1,171,189)	$ (1,134,438)
Cash, Cash Equivalents, and Short-term Investments		6,600
Debt Instrument, Unamortized Discount		26,000
Long-term Debt		165,317	227,043
Long-term Debt, Current Maturities, Including Due to Related Parties		13,285	$ 59,155
Interest Payable		$ 11,200
Subsequent Event [Member] | DSM International B.V. and Vivo Capital, LLC. [Member]
Proceeds from Issuance or Sale of Equity	$ 50,000

Note 2 - Summary of Significa33

Note 2 - Summary of Significant Accounting Policies (Details Textual)	Jun. 05, 2016$ / sharesshares	Jun. 30, 2017$ / sharesshares	Dec. 31, 2016$ / sharesshares	Jun. 04, 2016shares
Common Stock, Par or Stated Value Per Share | $ / shares	$ 0.0001	$ 0.0001	$ 0.0001
Common Stock, Shares Authorized | shares	250,000,000	250,000,000	500,000,000	500,000,000
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	15

Note 3 - Fair Value of Financ34

Note 3 - Fair Value of Financial Instruments (Details Textual) $ in Thousands, BRL in Millions	May 11, 2017	Apr. 21, 2017USD ($)shares	Dec. 31, 2016USD ($)	Jun. 30, 2017USD ($)	Jun. 30, 2017BRL
Loans Payable				$ 16,600
Long-term Line of Credit				49,800
Convertible Debt				99,000
Loans Payable, Fair Value Disclosure				13,400
Lines of Credit, Fair Value Disclosure				32,600
Convertible Debt, Fair Value Disclosures				95,800
Fair Value Assumptions, Risk Free Interest Rate	1.93%
Fair Value Assumptions, Expected Volatility Rate	80.00%		45.00%
Banco Pine July 2012 Loan Agreement [Member] | Interest Rate Swap [Member]
Derivative, Notional Amount				$ 6,700	BRL 22
Derivative, Fixed Interest Rate				3.94%	3.94%
SweeGen Common Stock [Member]
Equity Method Investment, Aggregate Cost		$ 3,200
Fair Value Inputs, Discount Rate		40.00%
Fair Value Assumptions, Risk Free Interest Rate		0.92%
Fair Value Assumptions, Expected Dividend Rate		0.00%
Fair Value Assumptions, Expected Volatility Rate		45.00%
Blue California [Member] | Intellectual Property License and Strain Access Agreement [Member] | SweeGen Common Stock [Member]
Shares Received in Satisfaction of Payment Obligation | shares		850,115
Fair Value, Inputs, Level 3 [Member] | Derivative Liability, Compound Embedded Derivatives [Member]
Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value			$ 4,135	$ 56,222
Derivative Liabilities [Member] | Fair Value, Inputs, Level 3 [Member] | Derivative Liability, Compound Embedded Derivatives [Member]
Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value			$ 4,100	$ 56,200

Note 3 - Fair Value of Financ35

Note 3 - Fair Value of Financial Instruments - Fair Value, Assets, and Liabilities Measured on Recurring Basis (Details) - Fair Value, Measurements, Recurring [Member] - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Total financial assets	$ 10,449	$ 2,922
Compound embedded derivative liability	56,222	4,135
Currency interest rate swap derivative liability	2,384	3,343
Total financial liabilities	58,606	7,478
Money market funds	5,078	1,549
Certificates of deposit	5,371	1,373
Fair Value, Inputs, Level 1 [Member]
Total financial assets	10,449	2,922
Money market funds	5,078	1,549
Certificates of deposit	5,371	1,373
Fair Value, Inputs, Level 3 [Member]
Compound embedded derivative liability	56,222	4,135
Currency interest rate swap derivative liability	2,384	3,343
Total financial liabilities	$ 58,606	$ 7,478

Note 3 - Fair Value of Financ36

Note 3 - Fair Value of Financial Instruments - Reconciliation for Compound Embedded Derivative Liability (Details) - Fair Value, Inputs, Level 3 [Member] - Derivative Liability, Compound Embedded Derivatives [Member] $ in Thousands	6 Months Ended
	Jun. 30, 2017USD ($)
Balance, compound embedded derivative liabilities	$ 4,135
Gain from change in fair value of derivative liabilities (in statements of operations)	(32,210)
Additions	93,675
Derecognition on extinguishment or conversion	(9,378)
Balance, compound embedded derivative liabilities	$ 56,222

Note 3 - Fair Value of Financ37

Note 3 - Fair Value of Financial Instruments - Market-based Assumption and Estimates for Compound Embedded Derivative Liabilities Valuation (Details) - $ / shares	May 11, 2017	Jun. 30, 2017	Dec. 31, 2016
Fair Value Assumptions, Risk Free Interest Rate	1.93%
Fair Value Assumptions, Expected Volatility Rate	80.00%		45.00%
Probability of change in control	5.00%	5.00%	5.00%
Share Price	$ 4.95	$ 3.18	$ 0.73
Estimated conversion dates
Minimum [Member]
Fair Value Assumptions, Risk Free Interest Rate		1.29%	0.55%
Fair Value Assumptions, Expected Dividend Rate		4.50%	12.80%
Fair Value Assumptions, Expected Volatility Rate		45.00%
Credit spread		3.15%	11.59%
Estimated conversion dates	2,017	2,017	2,017
Maximum [Member]
Fair Value Assumptions, Risk Free Interest Rate		1.93%	1.31%
Fair Value Assumptions, Expected Dividend Rate		28.93%	22.93%
Fair Value Assumptions, Expected Volatility Rate		80.00%
Credit spread		27.57%	21.64%
Estimated conversion dates	2,022	2,022	2,019

Note 3 - Fair Value of Financ38

Note 3 - Fair Value of Financial Instruments - Derivative Instruments Classification (Details) - Gain (Loss) From Change in Fair Value of Derivative Instruments [Member] - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
(Loss) gain from change in fair value of derivative instruments	$ 35,775	$ 20,934	$ 38,114	$ 42,612
Embedded Derivative Financial Instruments [Member]
(Loss) gain from change in fair value of derivative instruments	35,814	19,659	36,315	40,492
Currency Interest Rate Swap [Member]
(Loss) gain from change in fair value of derivative instruments	$ (39)	$ 1,275	$ 1,799	$ 2,120

Note 4 - Balance Sheet Compon39

Note 4 - Balance Sheet Components (Details Textual) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016
Property, Plant and Equipment, Gross	$ 141,088		$ 141,088		$ 140,930
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment	91,785		91,785		87,195
Depreciation, Depletion and Amortization			5,550	$ 5,720
Property, Plant and Equipment, Including Capital Leases [Member]
Depreciation, Depletion and Amortization	2,700	$ 2,800	5,400	$ 5,700
Capital Lease Obligations [Member]
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment	300		300		600
Capital Lease Obligations [Member] | Machinery and Equipment, Furniture and Office Equipment Under Capital Lease [Member]
Property, Plant and Equipment, Gross	$ 3,400		$ 3,400		$ 3,100

Note 4 - Balance Sheet Compon40

Note 4 - Balance Sheet Components - Inventory, Current (Details) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Raw materials	$ 2,937	$ 3,159
Work-in-process	1,379	1,848
Finished goods	1,413	1,206
Inventories	$ 5,729	$ 6,213

Note 4 - Balance Sheet Compon41

Note 4 - Balance Sheet Components - Property, Plant and Equipment (Details) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Property, plant and equipment	$ 141,088	$ 140,930
Less: accumulated depreciation and amortization	(91,785)	(87,195)
Property, plant and equipment, net	49,303	53,735
Machinery and Equipment [Member]
Property, plant and equipment	84,785	82,688
Leasehold Improvements [Member]
Property, plant and equipment	38,770	38,785
Computer Equipment and Software [Member]
Property, plant and equipment	9,619	9,585
Building [Member]
Property, plant and equipment	4,630	4,699
Furniture and Fixtures [Member]
Property, plant and equipment	2,324	2,333
Vehicles [Member]
Property, plant and equipment	133	164
Land [Member]
Property, plant and equipment	460	460
Construction in Progress [Member]
Property, plant and equipment	$ 367	$ 2,216

Note 4 - Balance Sheet Compon42

Note 4 - Balance Sheet Components - Other Assets, Noncurrent (Details) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Recoverable taxes from Brazilian government entities	$ 15,443	$ 13,723
Cost-method investment	3,233
Deposits on property and equipment, including taxes	909	291
Other	1,198	1,450
Total other assets	$ 20,783	$ 15,464

Note 4 - Balance Sheet Compon43

Note 4 - Balance Sheet Components - Accrued and Other Current Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Withholding tax related to conversion of related party notes	$ 1,370	$ 1,370
Professional services	5,943	6,876
SMA relocation accrual	3,587	3,641
Accrued interest	4,133	4,847
Tax-related liabilities	2,741	2,610
Accrued vacation	2,274	2,034
Payroll and related expenses	3,512	4,310
Deferred rent, current portion	1,122	1,111
Contractual obligations to contract manufacturers	2,698
Other	1,895	2,389
Total accrued and other current liabilities	$ 29,275	$ 29,188

Note 5 - Debt and Mezzanine E44

Note 5 - Debt and Mezzanine Equity (Details Textual) $ / shares in Units, BRL in Millions	Jun. 30, 2017USD ($)$ / sharesshares	Jun. 06, 2017$ / shares	May 31, 2017USD ($)$ / sharesshares	May 11, 2017USD ($)$ / sharesshares	May 08, 2017USD ($)$ / sharesshares	May 02, 2017USD ($)shares	Apr. 17, 2017USD ($)	Jan. 11, 2017USD ($)	Dec. 28, 2016USD ($)	Dec. 01, 2016USD ($)	Oct. 26, 2016USD ($)	Oct. 13, 2016USD ($)	Jun. 05, 2016	May 10, 2016USD ($)$ / sharesshares	Feb. 15, 2016USD ($)$ / sharesshares	Feb. 15, 2016USD ($)$ / sharesshares	Oct. 20, 2015USD ($)	Oct. 14, 2015USD ($)$ / sharesshares	Jul. 29, 2015USD ($)$ / sharesshares	May 31, 2017USD ($)$ / sharesshares	Jan. 31, 2017USD ($)	Dec. 31, 2016USD ($)$ / shares	Oct. 31, 2016USD ($)	Mar. 31, 2016USD ($)	Mar. 31, 2016EUR (€)	Oct. 31, 2015USD ($)	Jul. 31, 2015USD ($)shares	May 31, 2014USD ($)$ / shares	Jan. 31, 2014USD ($)	Oct. 31, 2013USD ($)$ / shares	Aug. 31, 2013USD ($)	Jul. 31, 2012USD ($)	Jun. 30, 2017USD ($)$ / sharesshares	Mar. 31, 2017USD ($)	Jun. 30, 2016USD ($)	Jun. 30, 2017USD ($)$ / sharesshares	Jun. 30, 2017BRLshares	Jun. 30, 2016USD ($)	Dec. 31, 2015USD ($)	Nov. 30, 2015USD ($)	Jun. 30, 2017BRLshares	May 01, 2017	Apr. 13, 2017USD ($)shares	Feb. 28, 2017	Feb. 27, 2017	Dec. 31, 2016BRL	Oct. 27, 2016USD ($)	Oct. 21, 2016USD ($)	Jun. 24, 2016USD ($)	May 31, 2016USD ($)	Feb. 28, 2016shares	Feb. 12, 2016USD ($)shares	Mar. 31, 2014USD ($)	Dec. 31, 2013USD ($)	Oct. 04, 2013	Feb. 28, 2012USD ($)$ / shares
Share Price | $ / shares	$ 3.18			$ 4.95																		$ 0.73											$ 3.18			$ 3.18
Gain (Loss) on Derivative Instruments, Net, Pretax																																	$ 35,775,000		$ 20,934,000	$ 38,114,000		$ 42,612,000
Adjustments to Additional Paid in Capital, Dividends in Excess of Retained Earnings																				$ 8,600,000
Acquistion Cost for Equipment Under Guarantee	$ 1,800,000																																1,800,000			1,800,000					BRL 6
Long-term Line of Credit	49,800,000																																49,800,000			49,800,000
Proceeds from Issuance of Debt																																				12,455,000		9,950,000
Gain (Loss) on Extinguishment of Debt																				(1,900,000)				$ 4,200,000									(3,624,000)		(433,000)	(3,528,000)		(649,000)
Convertible Debt	99,000,000																																99,000,000			99,000,000
Debt Instrument, Unamortized Discount	26,000,000																																26,000,000			26,000,000
Long-term Debt	$ 165,317,000																					$ 227,043,000											$ 165,317,000			$ 165,317,000
Extinguishment of Debt, Amount																				40,200,000
Preferred Stock, Par or Stated Value Per Share | $ / shares	$ 0.0001																					$ 0.0001											$ 0.0001			$ 0.0001
Proceeds from Issuance of Convertible Preferred Stock																																				$ 50,661,000
Embedded Derivative Financial Instruments [Member]
Gain (Loss) on Derivative Instruments, Net, Pretax																																				$ 9,400,000
Series A Preferred Stock Converted Into Common Stock [Member]
Conversion of Stock, Shares Converted | shares																																				18,840	18,840
Due to Related Parties [Member]
Extinguishment of Debt, Amount																				$ 33,100,000
Series A Preferred Stock [Member]
Preferred Stock, Capital Shares Reserved for Future Issuance | shares					22,140
Preferred Stock, Stated Value | $ / shares			$ 1,000																	$ 1,000
Preferred Stock, Conversion Price Per Share to Common Stock | $ / shares		$ 17.25
Preferred Stock, Dividend Rate, Percentage					17.38%															17.38%
Preferred Stock, Anniversary Payment | $ / shares			$ 1,738																	$ 1,738
Convertible Preferred Stock, Beneficial Conversion Feature, Proceeds Allocated to Preferred Stock					$ 600,000
Convertible Preferred Stock, Proceeds Allocated to Preferred Stock					$ 0
Preferred Stock, Par or Stated Value Per Share | $ / shares					$ 0.0001
Series B Preferred Stock [Member]
Preferred Stock, Capital Shares Reserved for Future Issuance | shares			70,904																	70,904
Preferred Stock, Dividend Rate, Percentage			17.38%
Preferred Stock, Par or Stated Value Per Share | $ / shares			$ 0.0001																	$ 0.0001
Proceeds from Issuance of Convertible Preferred Stock																				$ 30,700,000
Derivative Liability	$ 34,700,000																																$ 34,700,000			$ 34,700,000
Series B Preferred Stock [Member] | Selling, General and Administrative Expenses [Member]
Stock Issuance Costs Recognized																																				$ 800
Series C Preferred Stock [Member]
Preferred Stock, Stated Value | $ / shares				$ 1,000
Conversion of Stock, Conversion Rate | $ / shares		$ 15
Private Placement February 2016 [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 0.15																																$ 0.15			$ 0.15
Debt Instrument, Interest Rate, Stated Percentage															13.50%	13.50%
Gates Foundation Purchase Agreement [Member]
Stock Issued During Period, Shares, New Issues | shares														292,398
Share Price | $ / shares														$ 17.10
Proceeds from Issuance of Private Placement														$ 5,000,000
Compound Annual Return														10.00%
Temporary Equity, Carrying Amount, Attributable to Parent														$ 5,000,000
May 2017 Offering Closing [Member]
Proceeds from Issuance or Sale of Equity																				50,200,000
May 2017 Offering Closing [Member] | Series A Preferred Stock and Warrants [Member]
Proceeds from Issuance or Sale of Equity																				22,140,000
May 2017 Offering Closing [Member] | Series B Preferred Stock and Warrants [Member]
Proceeds from Issuance or Sale of Equity																				$ 30,700,000
May 2017 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares			14,768,380																	14,768,380
Class of Warrant or Right, Term																				5 years
Derivative Liability			$ 39,500,000																	$ 39,500,000
May 2017 Warrants, Warrant 1 [Member]
Class of Warrant or Right, Common Stock Available for Conversion, Percentage			50.00%																	50.00%
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares			7,384,190																	7,384,190
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares			$ 7.80																	$ 7.80
May 2017 Warrants, Warrant 2 [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares			7,384,190																	7,384,190
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares			$ 9.30																	$ 9.30
Dilution Warrants [Member]
Preferred Stock Effective Conversion Price | $ / shares			$ 6.30																	$ 6.30
Derivative Liability			$ 4,400,000																	$ 4,400,000
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares			$ 0.0015																	$ 0.0015
JVCO Joint Venture [Member]
Equity Method Investment, Ownership Percentage																								25.00%
Maximum [Member] | Series A Preferred Stock [Member]
Beneficiary Ownership, Conversion Percentage, Maximum			9.99%																	9.99%
Minimum [Member] | Series A Preferred Stock [Member]
Beneficiary Ownership, Conversion Percentage, Maximum			4.99%																	4.99%
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio													15
Total [Member]
Debt Conversion, Converted Instrument, Shares Issued | shares																											2,000,000
Debt Conversion, Original Debt, Amount																											$ 70,000,000
Convertible Debt																											$ 5,000,000
Extinguishment of Debt, Amount																								$ 5,000,000
Debt Instrument, Repurchase Amount																								$ 3,700,000
Total [Member] | JVCO Joint Venture [Member]
Equity Method Investment, Ownership Percentage by Counterparty																								75.00%
Foris Ventures, LLC [Member] | Due to Related Parties [Member]
Extinguishment of Debt, Amount																				$ 27,000,000
Foris Ventures, LLC [Member] | Series B Preferred Stock [Member]
Debt Conversion, Converted Instrument, Shares Issued | shares																				30,728.589
Debt Conversion, Converted Instrument, Warrants or Options Issued | shares																				4,877,386
Naxyris S.A. [Member] | Due to Related Parties [Member]
Extinguishment of Debt, Amount																				$ 2,000,000
Naxyris S.A. [Member] | Series B Preferred Stock [Member]
Debt Conversion, Converted Instrument, Shares Issued | shares																				2,333.216
Debt Conversion, Converted Instrument, Warrants or Options Issued | shares																				370,404
Foris and Naxyris [Member] | Conversion of Common Stock Into Series C Preferred Stock [Member]
Conversion of Stock, Shares Converted | shares				1,394,706
Foris and Naxyris [Member] | Series C Preferred Stock [Member] | Conversion of Common Stock Into Series C Preferred Stock [Member]
Conversion of Stock, Shares Issued | shares				20,921
Conversion of All Outstanding Fidelity Notes for Aggregate Principal Amount of 2015 144A Notes [Member]
Debt Conversion, Original Debt, Amount									$ 19,100,000
Debt Conversion, Converted Instrument, Exchange Ratio of Converted Debt to Original Debt									1.25
Proceeds from Issuance of Debt								$ 19,100,000
Gain (Loss) on Extinguishment of Debt																																		$ 100,000
Convertible Debt [Member]
Long-term Debt	$ 54,471,000																					$ 78,981,000											$ 54,471,000			$ 54,471,000
Related Party Convertible Notes [Member]
Gain (Loss) on Extinguishment of Debt																													$ (9,400,000)
Long-term Debt	44,499,000																					42,754,000											44,499,000			44,499,000
Related Party Convertible Notes [Member] | The Second Tranche [Member]
Convertible Notes Exchanged and Cancelled																													$ 6,000,000
Convertible Promissory Notes, Period After Which Notes Will Be Due																													5 years
Debt Instrument, Convertible, Conversion Price, Interest Accrued																													10.00%
Unsecured Promissory Notes, 2016 [Member]
Long-term Debt	2,000,000																																2,000,000			2,000,000
Unsecured Promissory Notes, 2016 [Member] | Private Placement February 2016 [Member]
Proceeds from Issuance of Private Placement															$ 20,000,000
Debt Instrument, Face Amount															$ 2,000,000	$ 2,000,000																																				$ 18,000,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares															19,048	19,048																																				171,429
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares															$ 0.15	$ 0.15
Foris Ventures, LLC [Member] | Private Placement February 2016 [Member]
Proceeds from Issuance of Private Placement																$ 16,000,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares															152,381	152,381
Naxyris S.A. [Member] | Private Placement February 2016 [Member]
Proceeds from Issuance of Private Placement																$ 2,000,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares															19,048	19,048
Biolding Investment SA [Member] | Private Placement February 2016 [Member]
Proceeds from Issuance of Private Placement																$ 2,000,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares															19,048	19,048
DSM International B.V. [Member]
Proceeds from Issuance of Private Placement				$ 25,000,000
Ownership Percentage, Designated Director Threshold				4.50%
Reserved Second Tranche Securities				$ 25,000,000
Second Tranche Closing, Anniversary Payment				$ 5,000,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares				3,968,116
DSM International B.V. [Member] | Series B Preferred Stock [Member]
Stock Issued During Period, Shares, New Issues | shares				25,000
DSM International B.V. [Member] | Maximum [Member]
Designated Holder Maximum Common Stock Ownership				33.00%
Reserved Second Tranche Securities				$ 30,000,000
DSM International B.V. [Member] | Minimum [Member]
Reserved Second Tranche Securities				$ 25,000,000
Foris and Naxyris [Member] | Series C Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share | $ / shares				$ 0.0001
FINEP Credit Facility [Member]
Long-term Line of Credit	$ 500,000																					700,000											$ 500,000			$ 500,000					BRL 1.8					BRL 2.3
Guanfu Credit Agreement [Member] | Guanfu Holding Co., Ltd [Member] | Unsecured Debt [Member]
Debt Instrument, Redemption Price, Percentage											100.00%
Common Stock, Volume Weighted Average Closing Sale Price, Percentage											90.00%
Common Stock, Volume Weighted Average Closing Sale Price, Number of Trading Days											90 days
Line of Credit Facility, Maximum Borrowing Capacity											$ 25,000,000
Long-term Line of Credit																						25,000,000
Debt Instrument, Interest Rate, Stated Percentage											10.00%
Debt Instrument, Term											5 years
Fidelity Convertible Notes [Member]
Debt Instrument, Convertible, Conversion Price | $ / shares																																																								$ 106.023
Debt Instrument, Face Amount																										$ 57,600,000
Debt Instrument, Repurchase Amount																										8,800,000
Debt Instrument, Repurchased Face Amount																										9,700,000
Fidelity Convertible Notes [Member] | Convertible Subordinated Debt [Member]
Convertible Notes Payable																																																								$ 25,000,000
Debt Instrument, Interest Rate, Effective Percentage																																																								3.00%
Rule 144A Convertible Note Offering [Member]
Convertible Note Offering																												$ 75,000,000
Proceeds from Convertible Debt																												$ 72,000,000
Rule 144A Convertible Note Offering [Member] | Denominator [Member]
Debt Instrument, Convertible, Conversion Rate, Principle Amount | $ / shares																												$ 1,000
Rule 144A Convertible Note Offering [Member] | Reverse Stock Split [Member]
Debt Instrument, Convertible, Conversion Ratio		17.8073
Debt Instrument, Convertible, Conversion Price | $ / shares																		$ 56.16
Rule 144A Convertible Note Offering [Member] | Affiliated Entity [Member]
Amount of Convertible Debt Purchased by Affiliated Entities																										24,700,000
Debt Instrument, Face Amount																										57,600,000
Debt Instrument, Repurchase Amount																										18,300,000
Debt Instrument, Repurchased Face Amount																										22,900,000
Debt Instrument, Interest Rate, Stated Percentage																												6.50%
Rule 144A Convertible Note Offering [Member] | Total [Member]
Debt Instrument, Decrease, Forgiveness																										$ 9,700,000
Rule 144A Convertible Note Offering [Member] | Convertible Debt Securities [Member]
Debt Instrument, Interest Rate, Effective Percentage																												6.50%
Convertible Senior Notes, 9.5% [Member]
Debt Instrument, Convertible, Conversion Rate, Shares | shares																		48.3395
Debt Instrument, Convertible, Conversion Rate, Principle Amount | $ / shares																		$ 1,000
Debt Instrument, Convertible, Conversion Price | $ / shares																		$ 20.69
Convertible Note Substantial Change, Discount Rate Used in Calculate Value of Remaining Interest Payments		0.75%
Debt Instrument, Convertible Percentage of Average Price Per Share the Stock will be Valued upon Early Conversion		92.50%
Number of Trading Days Notes Become Convertible		10 days
Convertible Promissory Note, Additional Principal Amount Issued During Period																					$ 19,100,000
Debt Instrument, Decrease, Forgiveness																					$ 15,300,000
Convertible Debt, Aggregate Number of Shares Issued With Respect to the Initial Closing, Maximum Percentage									19.99%
Debt Instrument, Face Amount																		$ 57,600,000
Proceeds from Convertible Debt																	$ 54,400,000
Debt Instrument, Interest Rate, Stated Percentage																		9.50%
Convertible Senior Notes, 6.5% [Member]
Debt Instrument, Repurchase Amount																	18,300,000
Debt Instrument, Repurchased Face Amount																	22,900,000
Convertible Senior Notes, 3% [Member]
Debt Instrument, Repurchase Amount																	8,800,000
Debt Instrument, Repurchased Face Amount																	$ 9,700,000
The May 2016 Convertible Notes [Member] | Convertible Subordinated Debt [Member]
Debt Instrument, Face Amount																																																		$ 15,000,000
Proceeds from Convertible Debt												$ 14,900,000
The December 2016 Convertible Note [Member] | Convertible Subordinated Debt [Member]
Debt Instrument, Face Amount										$ 10,000,000
Proceeds from Convertible Debt										$ 9,900,000
The April 2017 Convertible Notes [Member] | Convertible Debt [Member]
Proceeds from Convertible Debt							$ 6,900,000
The April 2017 Convertible Notes [Member] | Convertible Debt [Member] | Maximum [Member]
Debt Instrument, Face Amount																																											$ 15,000,000
The April 2017 Convertible Notes, Initial Closing [Member] | Convertible Debt [Member]
Debt Instrument, Face Amount							$ 7,000,000
The Amended Notes [Member]
Convertible Debt Securities, Monthly Installment Discount						20.00%																																				10.00%
Convertible Debt Securities, Price Floor Payment Discount Rate						70.00%																																				80.00%
The Amended Notes [Member] | Convertible Debt [Member]
Debt Instrument, Monthly Installments, Percent of Installment Amount						118.00%
Debt Instrument, Additional Common Stock Payment, Maximum Percent of Aggregate Amount						50.00%
Debt Instrument, Threshold Amount of Dollar-weighted Volume of Common Stock						$ 200,000
Debt Instrument, Events of Default, Percentage of Amount can be Redeemed by Holders						118.00%
Debt Instrument, Events of Fundamental Transaction, Percentage of Amount can be Redeemed by Holders						118.00%
Debt Instrument, Convertible, Conversion Price | $ / shares		$ 28.50
Convertible Debt, Beneficial Common Stock Ownership, Maximum Percentage Except Under Specified Conditions						4.99%
Convertible Debt, Beneficial Common Stock Ownership, Maximum Percentage Under Specified Conditions						9.99%
Convertible Debt, Beneficial Common Stock Ownership, Maximum Percentage, Conditions, Number of Days After Written Notice						61 days
Convertible Debt, Aggregate Number of Shares Issued With Respect to the Initial Closing, Maximum | shares						3,792,779
Convertible Debt, Aggregate Number of Shares Issued With Respect to the Initial Closing, Minimum | shares	15.75																																15.75			15.75					15.75		218,817
Convertible Debt, Holders May Not Sell Shares, Price Floor, Threshold | $ / shares	$ 15																																$ 15			$ 15
Long-term Debt	$ 19,100,000																					9,900,000											$ 19,100,000			$ 19,100,000
The 3 Million Note [Member]
Debt Instrument, Fee Amount	3,000,000																																3,000,000			3,000,000
Proceeds from Convertible Debt	3,000,000
Total Purchase Agreement [Member] | Total [Member]
Debt Instrument, Face Amount																																$ 105,000,000
Unsecured Senior Convertible Promissory Notes [Member] | Total [Member] | Initial Closing [Member]
Debt Instrument, Interest Rate, Stated Percentage																																1.50%
Secured R&D Notes [Member] | Total [Member]
Convertible Debt, Including Interest																			$ 2,800
Extinguishment of Debt, Amount																								$ 1,300,000	€ 50,000
Replacement Notes [Member]
Long-term Line of Credit	$ 3,700,000																					3,700,000											$ 3,700,000			$ 3,700,000
Debt Instrument, Convertible, Conversion Price | $ / shares	$ 46.20																																$ 46.20			$ 46.20
Debt Instrument, Interest Rate, Effective Percentage																																												12.00%	1.50%
August 2013 Convertible Notes [Member] | Total and Temasek [Member]
Debt Instrument, Face Amount																															$ 73,000,000
Private Placement Convertible Notes, Period																															2 years
August 2013 Convertible Notes [Member] | Temasek [Member]
Extinguishment of Debt, Amount																															$ 35,000,000
Temasek Bridge Loan [Member] | Temasek [Member]
Debt Instrument, Interest Rate, Stated Percentage																																																							5.50%
First Tranche [Member] | Related Party Convertible Notes [Member]
Gain (Loss) on Extinguishment of Debt																														$ (19,900,000)
Convertible Promissory Notes, Period After Which Notes Will Be Due																														5 years
Debt Instrument, Convertible, Conversion Price | $ / shares																														$ 2.44
Convertible Notes, Discount Percentage to Determine Conversion Price																														15.00%
Convertible Note Discount, Number of Days for Trailing Weighted-average Closing Price																														60 days
Plant Manufacturing Production, Product Sales, Percentage																														5.00%
Convertible Notes, Recurring Term of Option to Prepay After Initial Payment Period																														180 days
Cancellation of Convertible Debt																														$ 44,200,000
Proceeds from Convertible Debt																														7,600,000
First Tranche [Member] | Related Party Convertible Notes [Member] | Total [Member]
Debt Instrument, Face Amount																														51,800,000
Extinguishment of Debt, Amount																														9,200,000
First Tranche [Member] | Related Party Convertible Notes [Member] | Temasek [Member]
Extinguishment of Debt, Amount																														35,000,000
Second Tranche [Member] | Related Party Convertible Notes [Member]
Future Cancellation of Debt, Amount																														$ 9,200,000
Second Tranche [Member] | Related Party Convertible Notes [Member] | Wolverine [Member]
Debt Instrument, Face Amount																																																						$ 3,000,000
The Second Tranche [Member] | Related Party Convertible Notes [Member]
Debt Instrument, Face Amount																													$ 34,000,000
The Second Tranche [Member] | Related Party Convertible Notes [Member] | Temasek [Member]
Convertible Notes Purchased																													25,000,000
The Second Tranche [Member] | Related Party Convertible Notes [Member] | Wolverine [Member]
Convertible Notes Purchased																													3,000,000
The Second Tranche [Member] | Related Party Convertible Notes [Member] | Total [Member]
Convertible Notes Purchased																													$ 6,000,000
Tranche I and Tranche II Notes [Member] | Related Party Convertible Notes [Member]
Debt Instrument, Convertible, Conversion Price | $ / shares	$ 7.425																																$ 7.425			$ 7.425
Convertible Debt	$ 22,100,000																					21,800,000											$ 22,100,000			$ 22,100,000
Debt Instrument, Unamortized Discount	0																					0											0			0
Tranche I Notes [Member] | Temasek Funding Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares			1,125,755																	1,125,755																															164,169
June 2016 Private Placement [Member]
Debt Instrument, Face Amount																																																	$ 5,000,000
Debt Instrument, Interest Rate, Stated Percentage																																																	13.50%
October 2016 Private Placement [Member] | Foris Ventures, LLC [Member] | Convertible Subordinated Debt [Member]
Debt Instrument, Face Amount																																																$ 6,000,000
Debt Instrument, Interest Rate, Stated Percentage																																																13.50%
October 2016 Private Placement [Member] | Ginkgo Bioworks, Inc. [Member] | Convertible Subordinated Debt [Member]
Debt Instrument, Face Amount																																															$ 8,500,000
Salisbury Note [Member] | Salisbury Partners, LLC [Member]
Debt Instrument, Face Amount																						$ 3,500,000
Debt Instrument, Interest Rate, Stated Percentage																						5.00%																								5.00%
Debt Instrument, Term																						13 years
Debt Instrument, Delinquency Penalty																						5.00%																								5.00%
Debt Instrument, Delinquency Penalty, Threshold																						5 days
Nikko Note [Member] | Nikko [Member]
Debt Instrument, Additional Equal Monthly Installments, Amount																						$ 100,000
Debt Instrument, Face Amount																						$ 3,900,000
Debt Instrument, Interest Rate, Stated Percentage																						5.00%																								5.00%
Debt Instrument, Term																						13 years
Debt Instrument, Delinquency Penalty																						5.00%																								5.00%
Debt Instrument, Delinquency Penalty, Threshold																						5 days
Debt Instrument, Percentage of Joint Venture Interests Owned By the Company Securing the Debt Instrument																						10.00%																								10.00%
Debt Instrument, Additional Payments Required in Four Monthly Installments																						$ 400,000
March 2014 Letter Agreement [Member]
Debt Conversion, Original Debt, Amount																				$ 3,400,000
Conversion of All Outstanding Fidelity Notes for Aggregate Principal Amount of 2015 144A Notes [Member]
Debt Conversion, Original Debt, Amount																				$ 3,700,000
Tranche II Notes [Member] | Temasek Funding Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares																																																			164,169
Hercules Technology Growth Capital, Inc. (Hercules) [Member] | Loan and Security Agreement [Member]
Line of Credit Facility, Maximum Borrowing Capacity																																								$ 30,960,000
Proceeds from Long-term Lines of Credit																																								15,960,000
Payments of Financing Costs																																								$ 1,450,000
Debt Instrument, Face Amount																																																					$ 25,000,000
Stegodon [Member] | Loan and Security Agreement [Member]
Debt Issuance Costs, Line of Credit Arrangements, Net	600,000																																600,000			600,000
Debt Instrumebt, Requirement, Maximum Monthly Repayment, Using Proceeds from Collaboration Agreement																							$ 1,000,000
Debt Instrument, Additional Monies Agreed to Apply Toward Repayment of Outstanding Loans, Maximum																																			$ 3,000,000			$ 3,000,000
Long-term Line of Credit	27,800,000																																27,800,000			27,800,000
Nossa Caixa and Banco Pine Agreements [Member]
Debt Instrument, Period of Interest Only QuarterlyPayments																																2 years
Long-term Line of Credit	10,000,000																					$ 11,100,000											10,000,000			10,000,000
Certain Farnesene Production Assets Pledged as Collateral for Loans	15,700,000																																15,700,000			15,700,000					BRL 52
Collateral Provided by Company Certain Equipment and Other Tangible Assets, Amount																																				20,600,000	BRL 68
Debt Instrument, Face Amount	$ 15,700,000																																$ 15,700,000			$ 15,700,000					BRL 52
Debt Instrument, Interest Rate, Stated Percentage																																5.50%
Temasek [Member]
Debt Conversion, Original Debt, Amount																			$ 71,000,000
Temasek [Member] | Temasek Warrant 1 [Member]
Class of Warrant or Right, Term																			10 years
Temasek [Member] | Temasek Warrant 2 [Member]
Class of Warrant or Right, Numerator One																			30.60%
Class of Warrant or Right, Denominator One																			69.40%
Class of Warrant or Right, Numerator Two																			13.30%
Class of Warrant or Right, Denominator Two																			86.70%
Temasek [Member] | Temasek Warrant Three [Member]
Class of Warrant or Right, Threshold Number of Securities | shares																			133,334
Class of Warrant or Right, Common Stock Shares Used In Calculation | shares																			58,690
Temasek [Member] | The 2013 Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares	846,683																		66,667														846,683			846,683					846,683
Class of Warrant or Right, Outstanding | shares	1,289,924																																1,289,924			1,289,924					1,289,924
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 0.15																		$ 0.01														$ 0.15			$ 0.15
Temasek [Member] | If Total R&D Warrant is Exercised in Full [Member] | Temasek Warrant Three [Member]
Class of Warrant or Right, Common Stock Shares Used In Calculation | shares																			58,690
Temasek [Member] | Rule 144A Convertible Notes [Member]
Convertible Notes Payable																			$ 10,000,000
Total [Member]
Debt Conversion, Original Debt, Amount																			70,000,000
Convertible Notes Payable																			$ 25,000,000
Total [Member] | Total Funding Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares																			1,261,612
Class of Warrant or Right, Term																			5 years
Total [Member] | Total R&D Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares																			1,333,334
Total [Member] | Temasek Warrant 1 [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares																			978,525
Total [Member] | Temasek Warrant 2 [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares																			133,334
Total [Member] | Tranche I and Tranche II Notes [Member]
Convertible Notes Payable																			$ 15,300,000
Total [Member] | Rule 144A Convertible Notes [Member]
Convertible Notes Payable																			$ 9,700,000
Total and Temasek [Member]
Debt Instrument, Convertible, Conversion Price | $ / shares																			$ 34.50
Interest Expense, Debt																																							$ 39,200,000

Note 5 - Debt and Mezzanine E45

Note 5 - Debt and Mezzanine Equity - Debt Components (Details) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Debt	$ 165,317	$ 227,043
Less: current portion	(13,285)	(59,155)
Long-term debt, net of current portion	152,032	167,888
Contingently Redeemable Common Stock [Member]
Mezzanine Equity	5,000	5,000
Convertible Preferred Stock [Member]
Mezzanine Equity	12,830
Stegodon [Member]
Debt	27,999	27,658
BNDES Credit Facility [Member]
Debt	577	1,172
FINEP Credit Facility [Member]
Debt	534	696
Guanfu Credit Facility [Member]
Debt	20,645	19,564
Credit Facility [Member]
Debt	49,755	49,090
Long-term debt, net of current portion	48,874
Convertible Debt [Member]
Debt	54,471	78,981
Long-term debt, net of current portion	52,954
Loans Payable [Member]
Debt	14,592	26,527
Long-term debt, net of current portion	9,406
Related Party Convertible Notes [Member]
Debt	44,499	42,754
Long-term debt, net of current portion	40,798
Related Party Loan Payable [Member]
Debt	2,000	$ 29,691
Long-term debt, net of current portion

Note 5 - Debt and Mezzanine E46

Note 5 - Debt and Mezzanine Equity - Long-term Debt Instruments (Details) - USD ($) $ in Thousands		Jun. 30, 2017	Dec. 31, 2016
2017 (remaining six months)		$ 12,074
2,018		68,048
2,019		108,252
2,020		5,059
2,021		29,847
Thereafter		4,057
Total future minimum payments		227,337
Less: amount representing interest(1)	[1]	(62,020)
Present value of minimum debt payments		165,317
Less: current portion		(13,285)
Long-term debt, net of current portion		152,032	$ 167,888
Related Party Convertible Notes [Member]
2017 (remaining six months)		558
2,018		20,448
2,019		34,913
2,020
2,021
Thereafter
Total future minimum payments		55,919
Less: amount representing interest(1)	[1]	(11,421)
Present value of minimum debt payments		44,498
Less: current portion		(3,700)
Long-term debt, net of current portion		40,798
Convertible Debt [Member]
2017 (remaining six months)		4,123
2,018		8,636
2,019		68,097
2,020
2,021
Thereafter
Total future minimum payments		80,856
Less: amount representing interest(1)	[1]	(26,385)
Present value of minimum debt payments		54,471
Less: current portion		(1,517)
Long-term debt, net of current portion		52,954
Loans Payable [Member]
2017 (remaining six months)		1,426
2,018		5,268
2,019		2,665
2,020		2,559
2,021		2,451
Thereafter		4,057
Total future minimum payments		18,426
Less: amount representing interest(1)	[1]	(3,834)
Present value of minimum debt payments		14,592
Less: current portion		(5,186)
Long-term debt, net of current portion		9,406
Related Party Loan Payable [Member]
2017 (remaining six months)		2,487
2,018
2,019
2,020
2,021
Thereafter
Total future minimum payments		2,487
Less: amount representing interest(1)	[1]	(487)
Present value of minimum debt payments		2,000
Less: current portion		(2,000)
Long-term debt, net of current portion
Credit Facility [Member]
2017 (remaining six months)		3,480
2,018		33,696
2,019		2,577
2,020		2,500
2,021		27,396
Thereafter
Total future minimum payments		69,649
Less: amount representing interest(1)	[1]	(19,893)
Present value of minimum debt payments		49,756
Less: current portion		(882)
Long-term debt, net of current portion		$ 48,874
[1]	includes debt discount & issuance cost associated with related party & non-related party debt which will accrete to interest expense under the effective interest method over the term of the debt.

Note 6 - Commitments and Cont47

Note 6 - Commitments and Contingencies (Details Textual) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016
Purchase Obligation	$ 900		$ 900		$ 800
Contractual Obligation	600		600		600
Operating Leases, Rent Expense	1,400	$ 1,400	2,800	$ 2,700
Liabilities for Guarantees on Long-Duration Contracts, Guaranteed Benefit Liability, Net	0		0		$ 0
Manufacturing Agreement, Aprinnova JV [Member]
Contractual Obligation	$ 10,000		$ 10,000

Note 6 - Commitments and Cont48

Note 6 - Commitments and Contingencies - Future Minimum Payments for Lease Obligations (Details) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Capital leases 2017 (remaining nine months)	$ 530
Operating leases 2017 (remaining nine months)	3,406
Total lease obligations 2017 (remaining nine months)	3,936
Capital leases 2018	106
Operating leases 2018	6,889
Total lease obligations 2018	6,995
Capital leases 2019	22
Operating leases 2019	6,776
Total lease obligations 2019	6,798
Capital leases 2020	0
Operating leases 2020	7,006
Total lease obligations 2020	7,006
Capital leases 2021	0
Operating leases 2021	7,242
Total lease obligations 2021	7,242
Capital leases thereafter	0
Operating leases thereafter	10,958
Total lease obligations thereafter	10,958
Total future minimum capital lease payments	658
Total future minimum operating lease payments	42,277
Total future minimum lease payments	42,935
Less: amount representing interest	(27)
Present value of minimum lease payments	631
Less: current portion	(598)	$ (922)
Capital lease obligation, net of current portion	$ 33	$ 334

Note 7 - Joint Ventures and N49

Note 7 - Joint Ventures and Noncontrolling Interest (Details Textual)	Jun. 30, 2017
Aprinnova JV [Member]
Noncontrolling Interest, Ownership Percentage by Parent	50.00%

Note 7 - Joint Ventures and N50

Note 7 - Joint Ventures and Noncontrolling Interest - Variable Interest Entities (Details) - Variable Interest Entity, Primary Beneficiary [Member] - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Assets	$ 32,541	$ 30,778
Liabilities	$ 2,221	$ 333

Note 7 - Joint Ventures and N51

Note 7 - Joint Ventures and Noncontrolling Interest - Noncontrolling Interest (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Balance, noncontrolling interest	$ 937
Balance, noncontrolling interest	937
Noncontrolling Interest [Member]
Balance, noncontrolling interest	937	$ 0
Acquisition of noncontrolling interest	0	114
Balance, noncontrolling interest	$ 937	$ 114

Note 8 - Significant Agreemen52

Note 8 - Significant Agreements (Details Textual)	Jan. 15, 2018USD ($)	May 08, 2017USD ($)	Apr. 21, 2017shares	Jan. 15, 2017USD ($)	Nov. 30, 2016USD ($)	Sep. 30, 2016	Jul. 25, 2016USD ($)	Mar. 08, 2016USD ($)	Apr. 30, 2014USD ($)	Jun. 30, 2017USD ($)	Dec. 31, 2016USD ($)	Jun. 30, 2016USD ($)$ / sharesshares	Apr. 30, 2016	Sep. 30, 2015USD ($)	Mar. 31, 2015USD ($)	Mar. 31, 2014USD ($)	Mar. 31, 2013USD ($)	Jun. 30, 2017USD ($)	Jun. 30, 2016USD ($)$ / sharesshares	Jun. 30, 2017USD ($)	Mar. 31, 2017USD ($)	Jun. 30, 2016USD ($)$ / sharesshares	Apr. 30, 2017USD ($)
At the Market Offering [Member]
Commission Rate								3.00%
Stock Issued During Period, Value, New Issues																				$ 0
Common Stock, Value, Subscriptions								$ 50,000,000		$ 50,000,000								$ 50,000,000		50,000,000
Ginkgo Collaboration Note [Member] | Secured Promissory Note [Member]
Debt Instrument, Face Amount																							$ 3,000,000
Technology Investment Agreement with DARPA [Member]
Maximum DARPA Funding to be Received if all Milestones are Achieved														$ 35,000,000
Collaboration Agreement Period														4 years
Collective Obligation Due														$ 15,500,000
Revenue from Related Parties																		4,700,000	$ 2,300,000	5,700,000		$ 3,500,000
Firmenich [Member]
Additional Grants and Collaboration Funding																				5,000,000
Firmenich [Member] | Collaborative Arrangement [Member]
Revenue from Related Parties																		2,100,000	1,300,000	3,200,000		4,300,000
Firmenich [Member] | Flavors and Fragrances Compounds [Member]
Collaboration Agreement Period																	10 years
Collaboration Agreement, Automatic Renewal Period																	3 years
Collaborative Agreement, Notice Requirement before Terminating Current Term, Minimum																	1 year
Collaboration Agreement Annual Funding Year One																	$ 10,000,000
Collaboration Agreement Annual Funding Year Three															$ 10,000,000
Collaboration Agreement Annual Funding Year Two																$ 10,000,000
Firmenich [Member] | Flavors and Fragrances Compounds [Member] | Master Collaboration Agreement [Member]
Sales Margin Company Percentage Split																	30.00%
Sales Margin Collaborator Percentage Split																	70.00%
Return Required for Collaboration Partner Before Adjusting Split on Sales Margin																	$ 15,000,000
Sales Margin Company Percentage Split Following Return Requirements																	50.00%
Success Bonus																	$ 2,500,000
Revenue from Related Parties																		900,000	2,600,000	2,100,000		4,600,000
Firmenich [Member] | Flavors and Fragrances Compounds [Member] | Amended Collaboration Agreement [Member]
Royalty Rate, Percent of Net Revenue											10.00%
Kuraray [Member] | Collaborative Arrangement [Member]
Collaboration Agreement Period																2 years
Revenue from Related Parties																		100,000	400,000	300,000		800,000
Proceeds from Collaborators				$ 500,000					$ 2,000,000						$ 2,000,000	$ 4,000,000
Deferred Revenue					$ 1,000,000
Collaborative Agreement Number Of Installments					2											2
Kuraray [Member] | Collaborative Arrangement [Member] | Scenario, Forecast [Member]
Proceeds from Collaborators	$ 500,000
Kuraray [Member] | Product Sales [Member]
Revenue from Related Parties																		1,900,000	200,000	3,600,000		200,000
Nenter & Co., Inc. [Member]
Value-share Arrangement, Amount Receiable, Remainder of Fiscal Year										2,400,000								2,400,000		2,400,000
Loss on Contract Termination		$ 2,500,000
Nenter & Co., Inc. [Member] | Supply Agreements [Member]
Supply Agreement, Renewable Terms													5 years
Revenue from Related Parties																		6,600,000	0	8,900,000		30,000
Givaudan International, SA [Member] | Collaborative Arrangement [Member]
Semi Annual Installments, Amount												$ 3,000,000
Revenue from Related Parties																		1,500,000	$ 0	3,000,000		$ 0
Proceeds from Collaborators												12,000,000
Givaudan International, SA [Member] | Collaborative Arrangement [Member] | Deferred Revenue [Member]
Proceeds from Collaborators										3,000,000	$ 3,000,000	$ 3,000,000
Ginkgo Bioworks [Member]
Royalty Percentage												10.00%							10.00%			10.00%
Collaboration Agreement Period						3 years
Collaboration Agreement, Automatic Renewal Period						1 year
Collaborative Agreement, Notice Requirement before Terminating Current Term, Minimum						90 days
Collaborative Agreement, Notice Requirement before Terminating Current Term Due to Lack of Commitment						30 days
Revenue from Related Parties																				0
Collaboration Agreement, Common Stock Options Agreed to Issue, Term Exercisable from Date of Issuance												1 year
Collaboration Agreement, Common Stock Options Agreed to Issue | shares												333,334							333,334			333,334
Collaboration Agreement, Common Stock Options Agreed to Issue, Exercise Price Per Share | $ / shares												$ 7.50							$ 7.50			$ 7.50
Proceeds from Collaborators							$ 15,000,000					$ 20,000,000								0	$ 5,000,000
Collaborative Agreement Number Of Installments												2
Ginkgo Bioworks [Member] | Ginkgo Collaboration Agreement [Member]
Accounts Payable										$ 1,500,000								1,500,000		1,500,000
Revenue from Related Parties																		0	$ 0	0		$ 0
Blue California [Member] | Intellectual Property License and Strain Access Agreement [Member]
Accounts Receivable, Gross																							$ 10,000,000
Revenue from Related Parties											$ 10,000,000							$ 2,700,000	$ 0	$ 2,700,000		$ 0
Blue California [Member] | Intellectual Property License and Strain Access Agreement [Member] | SweeGen Common Stock [Member]
Shares Received in Satisfaction of Payment Obligation | shares			850,115

Note 9 - Goodwill and Intangi53

Note 9 - Goodwill and Intangible Assets - Intangible Assets and Goodwill (Details) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2017	Dec. 31, 2016
Goodwill, carrying amount	$ 560	$ 560
Goodwill, net carrying value	560	560
Intangible assets impairment and accumulated amortization	(9,332)	(9,332)
Goodwill and intangible assets, net	560	560
Goodwill and intangible assets, gross	9,892	9,892
Acquired Licenses and Permits [Member]
Accumulated amortization of intangible assets	(772)	(772)
In-process research and development, carrying amount	$ 772	772
Acquired licenses and permits, useful life (Year)	2 years
In Process Research and Development, Indefinite [Member]
In-process research and development, carrying amount	$ 8,560	8,560
In-process research and development	(8,560)	(8,560)
In-process research and development, net carrying value

Note 10 - Stock-based Compens54

Note 10 - Stock-based Compensation (Details Textual) $ in Millions	6 Months Ended
	Jun. 30, 2017USD ($)
Restricted Stock Units (RSUs) [Member]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized	$ 8.5
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	2 years 328 days
Employee Stock Option [Member]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized	$ 8.5
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	2 years 328 days

Note 10 - Stock-based Compens55

Note 10 - Stock-based Compensation - Share-based Compensation, Stock Options and Stock Appreciation Rights Award Activity (Details) $ / shares in Units, $ in Thousands	6 Months Ended
	Jun. 30, 2017USD ($)$ / sharesshares
Outstanding (in shares) | shares	875,021
Outstanding, weighted average exercise price (in dollars per share) | $ / shares	$ 55.20
Options granted (in shares) | shares	192,569
Options granted, weighted average exercise price (in dollars per share) | $ / shares	$ 6.94
Options exercised (in shares) | shares	(133)
Options exercised, weighted average exercise price (in dollars per share) | $ / shares	$ 4.20
Options forfeited (in shares) | shares	(70,182)
Outstanding, weighted average exercise price (in dollars per share) | $ / shares	$ 47.87
Outstanding, weighted average remaining contractual life (Year)	7 years 3 days
Outstanding, aggregate intrinsic value | $	$ 440
Vested and expected to vest after June 30, 2017 (in shares) | shares	895,140
Vested and expected to vest after December 31, 2016, weighted average exercise price (in dollars per share) | $ / shares	$ 51.99
Options forfeited, weighted average exercise price (in dollars per share) | $ / shares	$ 27.03
Outstanding (in shares) | shares	997,275
Vested and expected to vest after December 31, 2016, weighted average remaining contractual life (Year)	6 years 277 days
Vested and expected to vest after December 31, 2016, aggregate intrinsic value | $	$ 310
Exercisable at June 30, 2017 (in shares) | shares	539,738
Exercisable at December 31, 2016, weighted average exercise price (in dollars per share) | $ / shares	$ 76.14
Exercisable at December 31, 2016, weighted average remaining contractual life (Year)	5 years 131 days
Exercisable at December 31, 2016, aggregate intrinsic value | $

Note 10 - Stock-based Compens56

Note 10 - Stock-based Compensation - Temporal Display of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity (Details) - Restricted Stock Units (RSUs) [Member] - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2017	Dec. 31, 2016
Outstanding, RSUs (in shares)	454,923
Outstanding, weighted average grant-date fair value (in dollars per share)	$ 17.48
Outstanding, weighted average grant-date fair value (in dollars per share)	$ 11.20	$ 17.48
Outstanding, weighted average remaining contractual life (Year)	1 year 233 days
Awarded (in shares)	354,117
Awarded (in dollars per share)	$ 6.74
Vested (in shares)	(106,833)
Vested (in dollars per share)	$ 22.33
Forfeited (in shares)	(35,871)
Forfeited (in dollars per share)	$ 13.76
Expected to vest after June 30, 2017 (in shares)	501,550
Expected to vest after December 31, 2016, weighted average grant-date fair value (in dollars per share)	$ 11.56
Expected to vest after December 31, 2016, weighted average remaining contractual life (Year)	1 year 164 days
Outstanding, RSUs (in shares)	666,336	454,923

Note 10 - Stock-based Compens57

Note 10 - Stock-based Compensation - Employee Service Share-based Compensation, Allocation of Recognized Period Costs (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Allocated share-based compensation expense	$ 1,038	$ 1,789	$ 2,684	$ 3,840
Research and Development Expense [Member]
Allocated share-based compensation expense	441	485	925	976
Selling, General and Administrative Expenses [Member]
Allocated share-based compensation expense	$ 597	$ 1,304	$ 1,759	$ 2,864

Note 10 - Stock-based Compens58

Note 10 - Stock-based Compensation - Share-based Payment Award, Stock Options, Valuation Assumptions (Details) - Employee Stock Option [Member]	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Expected dividend yield
Risk-free interest rate	1.82%	1.40%	1.82%	1.40%
Expected term (Year)	5 years 138 days	6 years 58 days	5 years 138 days	6 years 58 days
Expected volatility	85.70%	72.50%	85.70%	72.50%

Note 11 - Related Party Trans59

Note 11 - Related Party Transactions (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016	Jul. 31, 2015
Convertible Debt	$ 99,000,000		$ 99,000,000
Debt Instrument, Unamortized Discount	26,000,000		26,000,000
Novvi LLC [Member]
Equity Method Investments	60,000		60,000
DSM International B.V. [Member]
Revenue from Related Parties	100,000	$ 100,000	100,000	$ 100,000
Accounts Receivable, Related Parties	600,000		$ 600,000		$ 800,000
Total [Member]
Convertible Debt						$ 5,000,000
Total [Member] | Pilot Plant Agreements [Member]
Related Party Agreement Term			5 years
Due to Related Parties	1,400,000		$ 1,400,000		1,800,000
Related Party Convertible Notes [Member]
Convertible Debt	46,300,000		46,300,000		72,400,000
Debt Instrument, Unamortized Discount	5,100,000		5,100,000		6,700,000
Derivative Liability	41,000,000		41,000,000		$ 800,000
Derivative, Gain (Loss) on Derivative, Net	$ 22,300,000	$ 3,900,000	$ 20,000,000	$ 8,400,000

Note 12 - Income Taxes (Details

Note 12 - Income Taxes (Details Textual) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Income Tax Expense (Benefit)	$ 310	$ 138	$ 269	$ 253

Note 13 - Net Loss Per Share 61

Note 13 - Net Loss Per Share Attributable to Common Stockholders - Calculation of Basic and Diluted Net Loss Per Share of Common Stock (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Net income (loss)	$ 620	$ (13,566)	$ (36,751)	$ (28,874)
Less deemed dividend (capital distribution to related parties)	(8,648)		(8,648)
Less deemed dividend related to beneficial conversion feature on Series A preferred stock	(562)		(562)
Less cumulative dividends on Series A and Series B preferred stock	(1,675)		(1,675)
Net loss attributable to Amyris, Inc. common stockholders, basic	(10,265)	(13,566)	(47,636)	(28,874)
Interest on convertible debt		1,591		3,501
Accretion of debt discount		1,846		3,479
Loss (gain) from change in fair value of derivative instruments		$ (19,116)		$ (37,803)
Basic (in dollars per share)	$ (0.44)	$ (0.91)	$ (2.24)	$ (2)
Net loss attributable to Amyris, Inc. common stockholders, diluted	$ (10,265)	$ (29,245)	$ (47,636)	$ (59,697)
Basic (in shares)	23,155,874	14,874,135	21,226,013	14,426,247
Effect of dilutive convertible promissory notes (in shares)		2,652,275		2,827,714
Weighted-average common stock equivalents used in computing net loss per share of common stock, diluted (in shares)	23,155,874	17,526,410	21,226,013	17,253,961
Diluted (in dollars per share)	$ (0.44)	$ (1.67)	$ (2.24)	$ (3.46)

Note 13 - Net Loss Per Share 62

Note 13 - Net Loss Per Share Attributable to Common Stockholders - Antidilutive Securities Excluded From Computation of Earnings Per Share (Details) - shares		3 Months Ended		6 Months Ended
		Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Antidilutive securities (in shares)		24,806,045	6,152,377	24,806,045	6,152,377
Stock Options to Purchase Common Stock [Member]
Antidilutive securities (in shares)		997,275	948,603	997,275	948,603
Convertible Promissory Notes [Member]
Antidilutive securities (in shares)	[1]	6,270,734	4,489,743	6,270,734	4,489,743
Common Stock Subject to Repurchase [Member]
Antidilutive securities (in shares)		16,871,700	193,429	16,871,700	193,429
Restricted Stock Units (RSUs) [Member]
Antidilutive securities (in shares)		666,336	520,602	666,336	520,602
[1]	The potentially dilutive effect of convertible promissory notes was computed based on conversion ratios in effect as of the respective period end dates. A portion of the convertible promissory notes issued carries a provision for a reduction in conversion price under certain circumstances, which could potentially increase the dilutive shares outstanding. Another portion of the convertible promissory notes issued carries a provision for an increase in the conversion rate under certain circumstances, which could also potentially increase the dilutive shares outstanding.

Note 14 - Subsequent Events (De

Note 14 - Subsequent Events (Details Textual) - USD ($)	Aug. 07, 2017	Aug. 03, 2017	Aug. 02, 2017	Jun. 30, 2017	Jun. 30, 2016	May 11, 2017	Dec. 31, 2016
Preferred Stock, Par or Stated Value Per Share				$ 0.0001			$ 0.0001
Proceeds from Issuance of Convertible Preferred Stock				$ 50,661,000
Subsequent Event [Member] | August 2017 Vito Warrants [Member]
Class of Warrant or Right, Term		5 years
Subsequent Event [Member] | August 2017 Vito Dilution Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.0001
Preferred Stock Effective Conversion Price		$ 4.26
DSM International B.V. [Member]
Reserved Second Tranche Securities						$ 25,000,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights						3,968,116
Ownership Percentage, To Have Right To Designate One DSM Director						10.00%
Ownership Percentage, Designated Director Threshold						4.50%
Second Tranche Closing, Anniversary Payment						$ 5,000,000
DSM International B.V. [Member] | Subsequent Event [Member] | DSM Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			3,968,116
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 6.30
Class of Warrant or Right, Term	5 years
DSM International B.V. [Member] | Subsequent Event [Member] | DSM Dilution Warrant [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.0001
Preferred Stock Effective Conversion Price	6.30
Common Stock, Dividends, Per Share, Declared	$ 0.10
Vivo Capital LLC [Member] | Subsequent Event [Member] | Securities Purchase Agreement [Member]
Shares Issued, Price Per Share			$ 4.26
Stock Issued During Period, Shares, New Issues		2,826,711	2,826,711
Proceeds from Issuance or Sale of Equity		$ 24,800,000
Vivo Capital LLC [Member] | Subsequent Event [Member] | August 2017 Vito Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			5,575,118
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 6.39
Vito Stockholder Agreement [Member] | Subsequent Event [Member]
Ownership Percentage, Designated Director Threshold		4.50%
Designated Holder Maximum Common Stock Ownership		33.00%
Maximum Number of Shares Registered, Percentage		25.00%
Series B Convertible Preferred Stock [Member] | DSM International B.V. [Member] | Subsequent Event [Member]
Stock Issued During Period, Shares, New Issues			25,000
Proceeds from Issuance of Convertible Preferred Stock	$ 24,800,000
Series D Convertible Preferred Stock [Member] | Vivo Capital LLC [Member] | Subsequent Event [Member] | Securities Purchase Agreement [Member]
Stock Issued During Period, Shares, New Issues		12,958	12,958
Preferred Stock, Par or Stated Value Per Share			$ 0.0001
Series D Preferred Stock [Member] | Subsequent Event [Member]
Beneficiary Ownership, Conversion Percentage, Minimum		9.99%
Preferred Stock, Stated Value		$ 1,000
Preferred Stock, Conversion Price Per Share to Common Stock		4.26
Common Stock, Dividends, Per Share, Declared		$ 0.0001